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Abstract

Breast reconstruction following mastectomy is increasing and implant-based breast
reconstruction is the most common surgical approach. Saline and silicone implants have
different cost and complication profiles and it is unclear which is the more cost-effective
option. A systematic review of the literature was undertaken to summarize the quality of
life data in breast reconstruction, specifically, previously published health state utility
values relevant to breast reconstruction. In addition, a cost-utility analysis was undertaken
from the perspective of the third-party payer, accounting for the most common
complications associated with saline and silicone implants. This demonstrated that
despite the increased initial cost of silicone implants, they are cost-effective with a
willingness-to-pay threshold of $50,000 (ICUR $52.26/QALY). Overall, silicone
implants provide improved quality of life with a marginal cost increase.
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Chapter 1
1. Chapter 1: Introduction

Overview
The purpose of this thesis is to compare silicone and saline implants in terms of costeffectiveness in the context of breast reconstruction. This chapter reviews the clinical
context of increasing demand for reconstructive breast surgery and the available
surgical options. In addition, a brief overview of the existing cost-effectiveness
analyses in breast reconstruction will be undertaken, highlighting the gaps in the
literature on comparison of implant types. Finally, the regulatory climate and the
present challenges in health care spending and planning will provide a framework
for the rationale for this project.

1.1. Clinical Context: Breast Cancer and The Increasing Rate of Mastectomy
Breast cancer is the most common cancer among Canadian women, affecting 1 in 8
women over their lifetime.(1) Although breast cancer continues to represent 13 percent of
cancer deaths among Canadian women, the mortality rate has declined over the past three
decades likely due to the increased use of screening mammography and improved breast
cancer treatments.(1,2)

Treatment goals and pathways are dictated by the stage of breast cancer at the time of
presentation and typically consist of surgical resection of the primary tumour with or
without chemotherapy and radiation. Surgical ablation of the primary tumour can be in
the form of either lumpectomy (i.e., breast conserving therapy) or mastectomy. In early
stage breast cancer (Stage I or II), lumpectomy followed by radiation is comparable to
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mastectomy in overall survival, although mastectomy is associated with a decreased rate
of local recurrence.(3–5)

Despite the more invasive nature of mastectomy, recent literature has shown that more
women are choosing mastectomy over breast conserving therapy.(6) Prophylactic
mastectomy is also increasing in frequency. Contralateral prophylactic mastectomy
reduces the relative risk of contralateral breast cancer by 95 percent in women who have
had breast cancer, reflecting an absolute risk reduction of approximately 20 to 25%.(7,8)
From 1998 to 2003, rates of contralateral prophylactic mastectomy increased
approximately 150 percent in women with invasive breast cancer.(9) The same trend has
been identified among women with ductal carcinoma in situ.(10) In addition, with the
widespread availability of testing for BRCA genetic mutations over the past two decades,
bilateral prophylactic mastectomy as a risk reducing strategy is increasingly chosen.(11)
The choice of mastectomy and or contralateral prophylactic mastectomy over breast
conserving therapy or unilateral mastectomy alone is multifactorial; however, women
who choose the former tend to be younger and of Caucasian race and to have private
insurance coverage, larger tumours and family histories of breast or ovarian
cancer.(6,8,9,12) The rationale behind the choice of surgical resection is incompletely
understood; however, fear of developing a cancer in the contralateral breast in addition to
the desire for a more symmetric reconstruction have been cited.(13)

2
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1.2. Overview of Breast Reconstruction
1.2.1. Need for Breast Reconstruction Surgery
The combination of early detection, improved treatment and patient preference for
mastectomy has contributed to a greater number of women surviving breast cancer with
significant mastectomy defects. Breast scars and deformities due to mastectomy can
decrease quality of life.(14–16) It is generally accepted that breast reconstruction
improves body image in women after mastectomy although factors such as personality
traits and body mass index may influence the degree of improvement in quality of
life.(17,18) Nonetheless, although many factors influence a woman’s decision to undergo
reconstructive breast surgery, it is likely that these elements have contributed to the
increased demand for breast reconstruction in recent years.

Breast reconstruction rates have increased in the past 20 years in both Canada and the
United States.(19,20) This has paralleled an increase in the rate of contralateral
prophylactic mastectomy since women undergoing bilateral mastectomies tend to have
higher rates of reconstruction.(21) An analysis of the United States Nationwide Inpatient
Sample between 1998 and 2008 revealed that 60 percent of women who had contralateral
prophylactic mastectomies underwent reconstruction while 81 percent of women
undergoing bilateral prophylactic mastectomy underwent immediate reconstruction.(21)
Additionally, the rate of reconstruction among women who had contralateral prophylactic
mastectomies rose by 3 percent per year during the study period. Not only have rates of
breast reconstruction increased, but the rate of implant-based reconstruction has also
increased by 11 percent per year from 1998 to 2008 in the United States.(19)
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In Ontario, the breast reconstruction rate increased from 19.3 percent in 2002 to 27.9
percent in 2008.(20) Unfortunately, there remains a significant geographic disparity
across the province in immediate breast reconstruction rates, which may be attributed to
access to a plastic surgeon.(20) In 2016, in an effort to increase access to breast
reconstruction, Cancer Care Ontario (CCO) recommended that all women undergoing
mastectomy be offered a consultation with a plastic surgeon to discuss breast
reconstruction.(22) In addition, dedicated hospital funding to support breast
reconstruction has been available since 2016 when CCO designated breast reconstruction
as a Quality-Based Procedure.(23) Although it is too early to assess the effects of these
changes, it is reasonable to expect rates of breast reconstruction to increase as a result.

1.2.2. Breast Reconstruction Options
Multiple techniques for breast reconstruction have been developed over the years and can
broadly be categorized into autologous breast reconstruction and implant-based
reconstruction. Both autologous and implant-based reconstructions can be performed as
immediate (i.e., completed at the same time as mastectomy) or delayed procedures.
Timing is influenced by a number of factors including tumour stage at presentation,
requirement for adjuvant treatment, plastic surgeon availability and patient preference.

1.2.2.1. Autologous Reconstruction
Autologous breast reconstruction involves use of a patient’s own tissues to reconstruct
the breast mound. It is especially helpful for patients who have undergone radiation as
implant-based reconstruction can be challenging in a radiated tissue bed.(24) Tissue can
be harvested either regionally with pedicled flaps or from distant sites requiring
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microvascular anastomosis at the recipient site. The abdomen is the most common donor
site for autologous breast reconstruction because an adequate volume of tissue is typically
available and is of similar skin colour and consistency to breast tissue. Further, for large
pendulous breasts, abdominal tissue is easily molded to match the contralateral breast
shape. The transverse rectus abdominis (TRAM) myocutaneous flap has been a
workhorse flap for autologous breast reconstruction. It results in good quality tissue for
reconstruction of the breast mound and has the benefit of reducing redundant abdominal
tissue, if desired. However, it is associated with donor site morbidity in the form of
abdominal bulging and hernias due to weakening of the abdominal wall
musculature.(25,26) The deep inferior epigastric (DIEP) flap avoids the donor site
morbidity of the TRAM flap by preserving the rectus abdominis muscle and as such does
not result in abdominal wall weakness.(26) Conversely, it may increase the frequency of
complications at the breast recipient site including fat necrosis and partial or complete
flap loss.(27) Other common flaps include the pedicled latissimus dorsi flap, which may
be considered in women without sufficient abdominal tissue for reconstruction.(28) It
may be used alone or in conjunction with implant-based reconstruction.

1.2.2.2. Implant-Based Reconstruction
Although autologous breast reconstruction has been found to be more cost-effective than
implant-based reconstruction,(29) not all patients desire or are candidates for autologous
reconstruction due to body habitus or personal choice. Implant-based breast
reconstruction utilizes a synthetic implant to reconstruct the breast mound and, as for
autologous reconstruction, can be either immediate or delayed. For either, the
reconstruction may be performed as a single-stage or two-stage procedure. In a single-
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stage procedure, the implant pocket is developed and a permanent implant is placed. A
two-stage procedure involves the initial placement of a tissue expander which acts to
stretch the skin and soft tissues to accommodate a permanent implant which is placed at a
later surgery following several months of serial expansion. Breast implants available in
North America must be approved by the Food and Drug Administration (FDA) in the
United States or Health Canada in Canada. Implants can be categorized by their shape,
texture and content.

1.2.2.3.

Types of Breast Implants

Breast implants available in North America are made with two types of fillers: silicone
and saline. Silicone gel breast implants were developed by Dow Corning in 1962.(30)
The evolution of breast implants is complex and can be confusing because of the
nomenclature of “generations” of implants which describe the various types. The first
generation of breast implants was characterized by a thick outer shell, firm interior gel,
anatomic shape and a Dacron patch which was sutured to the chest wall to keep the
implant in position.(31) Beginning in 1970, these were replaced by the second generation
of implants which featured a round shape, a smooth, thin outer shell and a less viscous
gel filler. An initial positive experience with these implants was characterized by a more
natural shape and feel. However, longer term follow-up demonstrated gel “bleed” (i.e.,
slow passage of silicone gel through an intact outer shell) and, more importantly, an
extremely high rate of implant rupture.(32) The third generation of implants attempted to
resolve these issues with a more cohesive gel filler and a thicker, low-bleed shell. These
implants, first introduced in 1982, also featured a textured surface option. The fourth
generation of implants was first introduced in 1993 and featured a more strongly cohesive
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gel filler within the same low-bleed shell of the third-generation devices but was
developed under strict regulatory control by the FDA with the intention of eventual reintroduction into the market.(33) The fifth generation of implants was first developed in
1993 and was characterized by a highly cohesive, form-stable gel. Like the fourthgeneration implants, these are available in smooth and textured surfaces with the same
low-bleed shell; however, these are also available as anatomic implants in addition to
round varieties.(31,33,34)

Saline implants were developed in the 1950s but early versions were limited by high rates
of deflation.(33) Eventually these were popularized in North America during the 1990s
when silicone implants were removed from the market due to safety concerns, which
included implant rupture, an association with connective tissue diseases and increased
risk of breast cancer.(35) After numerous studies concluded that the latter two concerns
were invalid, silicone implants were reintroduced in both Canada and the United States
following the standard premarket approval processes.(36,37) Saline implants continue to
be used but have higher complications rates including visible rippling, firm consistency
and greater potential for noticeable deflation and resultant re-operation.(38,39)
Conversely, potential advantages of saline implants include an ability to fill to volumes
larger than those offered with silicone implants, a lower cost and an alternative for
women who have inherent concerns about silicone gel implants.

The two principle classes of implant shape are round and anatomic (“tear drop”). The
theoretical advantage of an anatomic implant is the creation of a more naturally shaped
breast mound with decreased upper pole fullness relative to round implants. Importantly,
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the extent to which an implant holds its shape under the influence of gravity is influenced
by the filler. Therefore, anatomic implants with more highly cohesive gel filler tend to
maintain their upper pole shape against gravity. A recent study demonstrated that in the
breast reconstruction population, patients who received round implants were more likely
to undergo revision symmetry procedures than those who received anatomic
implants.(40) Despite this theoretical advantage, numerous other studies have been
unable to demonstrate a difference in appearance or quality of life between anatomic and
round implants.(34,41) Further, the use of anatomic implants can be complicated by
implant malposition, such as implant malrotation, and require subsequent reoperation for
correction.(31)

Both saline and silicone implants in current use have silicone elastomer shells that vary in
surface characteristics. Broadly, these surface qualities are characterized as “smooth” and
“texturized,” although textured implants have variable surface morphology based on
patented designs by device manufacturers. While all implants will result in capsule
formation, capsular contracture is less common with textured implants. (42) The textured
surface is particularly common in anatomically-shaped implants as the surface texture
helps maintain the implant position within the implant cavity. However, there are some
drawbacks to the textured surface, namely the evolving body of literature suggesting an
association with breast implant-associated anaplastic large cell lymphoma (BIAALCL).(43,44) While the understanding of this disease is still developing and the
reported incidence is low, rates reported in the literature are rising.(45) Rates of BIAALCL may rise over the coming years with increased awareness and surveillance.
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1.2.3. Summary of Clinical Problem
Saline and silicone-filled implants are used in both the breast augmentation and
reconstruction populations with good results. While silicone implants have been
associated with higher rates of capsular contracture,(46) they have also been associated
with improved patient satisfaction compared to patients with saline implants.(47) In
Canada, the cost of silicone implants may be twice the price of saline implants.(30) Since
satisfaction and rates of complications requiring reoperation differ between patients with
saline versus silicone implants, it would be useful to determine the option that is most
effective taking into account clinical outcomes, quality of life and cost.

1.3. Economic Context: Decision-Making in a Publicly-Funded Health Care System
In Canada, health care spending is among the highest internationally and is on the
rise.(48) In 2015, health expenditure reflected 10.4 percent of the gross domestic product
(GDP) and is expected to rise to 11.5 percent in 2017.(48) In a resource-constrained
system, it is important to consider the value for money achieved with health care
expenditures since spending in one area removes resources in other areas.

Economic analyses are decision-making tools used to inform choice and funding of
therapies or interventions with the goal of choosing the most economically effective
options.(49) There are multiple forms of economic analysis, differentiated by the number
and unit of measure of health outcomes (Table 1.1). Cost-minimization analysis compares
cost when patient outcomes are equal. Cost-benefit analysis examines the monetary value
of multiple patient outcomes. However, it is often challenging to assess the value of a
health state in monetary terms. Cost-effectiveness analysis measures cost against a single
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health outcome measured in natural units (e.g., life years gained). While this is a useful
method of analysis, it can be challenging to compare analyses measured in different
natural units (e.g., life years gained versus premature births avoided). Cost-utility analysis
measures patient outcomes using a common denominator: healthy years (e.g., quality
adjusted life years).(49)

Table 1.1 Economic Analyses
Method

Assumption

Number of Outcomes Unit of Outcome

Cost-minimization analysis

Patient outcomes equal

None

None

Cost-benefit analysis

Patient outcomes not equal

Many

Monetary

Cost-effectiveness analysis

Patient outcomes not equal

One

Natural Units

Cost-utility analysis

Patient outcomes not equal

One

Quality of Life

1.3.1. Cost-Utility Analysis in Breast Reconstruction
Cost-effectiveness analysis (CEA) is a type of economic evaluation that is used to
determine the value for money of various treatments and interventions.(49) A subtype of
CEA is cost-utility analysis (CUA), whereby cost is measured against health status, most
commonly expressed in quality-adjusted life-years (QALYs).(50,51) The advantage of
using a cost-utility analysis is that it facilitates comparisons of different interventions and
health states through a common denominator, the QALY. Comparisons may be made
across disease groups for which outcomes measured in natural units may not be directly
comparable (e.g., hip fractures avoided versus life years gained).

There are increasing numbers of cost-utility analyses examining breast reconstruction
options. Several have compared autologous and implant-based reconstruction (29,52–54)
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while others have examined adjuncts to surgery and surgical materials such as CT
angiography and acellular dermal matrix.(55,56) Overall, there is evidence to support
greater cost-effectiveness with autologous reconstruction. Unfortunately, not all women
are candidates for autologous reconstruction due to body habitus, comorbidities and
patient preference. In terms of implant-based reconstruction, no cost-utility analysis has
compared saline and silicone implants which are associated with different costs and
quality of life. There is a clear clinical demand for implant-based breast reconstruction.
However, given resource constraints, health care providers may be asked to justify use of
devices seen as more costly. A cost-utility analysis of saline and silicone implants would
provide helpful information to physicians, hospitals and policymakers when purchasing
implants for breast reconstruction.

A secondary consideration from the existing cost-utility analyses is choice of health state
utilities. Often CUAs estimate new utility values for the health states included in the
analysis. Although generating new health state utility values may allow for more accurate
assessment of the specific health state description used in a model, repeatedly surveying
physicians and patients is time-consuming and costly. Given the need for costeffectiveness analyses in resource-limited systems and the increasing rate of breast
reconstruction, understanding the existing published health state utility values and the
methods used to evaluate them is essential. Furthermore, developing strong estimates of
health state utility values is paramount to enhancing the external validity of a CUA
model.
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1.4. Rationale for Cost-Utility Analysis in Implant-Based Breast Reconstruction
Breast reconstruction is a recognized component of the cancer treatment pathway and
rates are increasing in both the United States and Canada.(20) Further, implant-based
reconstruction increased by 11 percent between 1998 to 2008 in the United States and
continues to be the most common type of breast reconstruction in North America.(19)
There is a clear clinical demand for implant-based breast reconstruction; however, there
are a wide variety of implant designs to choose from with varying advantages and
disadvantages. In a resource constrained health care system, whether publicly- or
privately-funded, it is essential to consider the cost-effectiveness of these treatment
options. An important element of implant-based breast reconstruction is implant choice.
Saline and silicone implants have different quality of life, safety and cost profiles. It is
essential to find cost-effective alternatives that continue to provide women seeking breast
reconstruction a high quality of life in the survivorship period. Further, outlining the costeffectiveness of implant alternatives may help health care providers justify the use of
interventions that are more costly but associated with improvements in quality of life.
Therefore, the first component of this study is an examination of the existing health state
utility values in breast reconstruction through a systematic review of the literature. The
second component of this study is a cost-utility analysis of saline and silicone implants
for immediate, unilateral, implant-based breast reconstruction.
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2. Chapter 2: A Systematic Review of Utility Measurements in Breast Reconstruction

Overview
This chapter reviews approaches to health status assessment and utility generation.
In addition, a systematic review of health state utility values in breast reconstruction
explores the existing literature supporting this component of economic analysis in
the breast reconstruction population. Utilities are summarized in a quantitative
analysis and methods of health status assessment in this field are compared to
existing guidelines. The results of this analysis can serve as a reference for utility
values for future cost-utility analyses in breast reconstruction.1

2.1. Introduction
Breast reconstruction is an integral component of the breast cancer treatment pathway
and rates are increasing in both the United States and Canada.(1,2) However, there are a
wide variety of approaches ranging from autologous to implant-based options. Factors
which may determine the best option for an individual woman include medical
comorbidities, body habitus, breast cancer characteristics and personal preferences.
Within these domains, there are a number of variables that can influence cost and quality
of life associated with the procedure, including the use of venous couplers, acellular
dermal matrices and implant type.(3–5) In a resource constrained health care system, it is
essential to consider the cost-effectiveness of these and other treatment options.

1

A portion of the work covered in Chapter 1 is included here as part of the Integrated Article Format.
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2.1.1. Cost-Utility Analysis
Cost-effectiveness analysis (CEA) is a type of economic evaluation that is used to
determine the value for money of treatments and interventions.(6) A subtype of CEA is
cost-utility analysis (CUA), whereby cost is measured against health status, most
commonly expressed in quality-adjusted life-years (QALYs).(7,8) The advantage of
using a cost-utility analysis is that it facilitates comparisons of different interventions and
health states through a common denominator, the QALY. This allows for comparisons
across disease groups for which outcomes measured in natural units may not be directly
comparable (e.g., hip fractures avoided versus life years gained). QALYs can be
calculated by multiplying the value and duration of a given health state.(8) The value of a
health state, known as the health state utility value (HSUV) or single index score, ranges
from zero (death) to 1 (perfect health).(8) States worse than death can have a value less
than zero. Thus, one QALY equates to one year of life lived in perfect health.

!"#$ = &'() ∗ +,-./012 14 ℎ6.7/ℎ 8/./6 (:6.-8)
1 !"#$ = 1 ∗ 1 :6.-

2.1.2. Health Status Assessment
Health state utility values can be generated through direct elicitation or indirect health
status assessment.(9) Direct elicitation methods include techniques such as visual
analogue scale (VAS), time trade-off (TTO) and standard gamble (SG) (Table 2.1).(8,9)
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Table 2.1 Direct Elicitation Methods
Method

Description

Visual Analogue Scale Respondents rank health states along a line with well-defined end points (e.g.,
perfect health and death) according to desirability. The utility of the impaired
health state is the fractional distance along the continuous scale.(8)
Time Trade-Off

Respondents choose between two alternatives: living x years in an impaired
health state or living in perfect health for y years (a shorter period of time). The
time period is varied until respondent finds the two choices equivalent. Then the
utility of the impaired health state is x/y.(9)

Standard Gamble

Respondents choose between remaining in an impaired health state or taking a
gamble, in which they may return to full health or die. The probability of death is
varied until the respondent finds the certainty and gamble equivalent. The utility
of the impaired health state is the probability of returning to full health at the
point of indifference.(9)

When using a VAS, individuals are asked to rank health states along a scale from best to
worst imaginable health or from perfect health to death.(8) Although attractive in its
simplicity, this method is limited by inconsistent anchors, context bias (i.e., where
valuation depends on number of states presented at the same time), scaling bias (i.e.,
reluctance to rate health states at extremes of the scale) and emphasis on rating rather
than choice, which does not have grounding in economic theory.(8,10) Time trade-off
and standard gamble both involve an element of choice and as such have stronger
grounding in economic theory. The time trade-off method asks respondents to choose
between living in an impaired health state for a period of time, x, and living in perfect
health for a shorter period of time, y. The time of x or y is then varied until the respondent
finds the choices equivalent. The utility is then y/x.(8,9) Standard gamble also presents a
choice to respondents, asking them to choose between staying in a state of impaired
health or taking a gamble in which they either return to full health or die. The probability
of returning to full health is then varied until the respondent is indifferent at which point
the probability is the utility of the impaired health state.(8,9)
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Indirect health status assessment is performed through administration of questionnaires
that address multiple domains of quality of life such as pain, physical functioning and
emotional well-being.(8) Questionnaires can either be generic, assessing a broad scope of
domains relevant to health in general, or specific to a given disease population.(9)
Generic tools allow for comparison across multiple disease groups but can be insensitive
to domains that are specific to particular disease populations.(11) For instance, breast
reconstruction impacts multiple domains such as body image and sexual functioning, but
these are not directly addressed in generic tools such as the Euro-Qol 5D (EQ5D).(12,13) However, condition-specific measures of quality of life decrease the
comparability of results across diseases. Because of this, disease-specific measures must
be mapped to a generic measure prior to being used in economic evaluations.(9)

Health status questionnaires can be classified as either preference-based or nonpreference-based measures. Non-preference-based measures ask respondents to depict
their health in different domains of quality of life and, in doing so, describe a health
state.(14) Preference-based measures capture the desirability of a health state.(9) The
latter, also referred to as multi-attribute utility scales, generate specific health states for
which a single index score (i.e., health state utility value) is calculated using preference
weights developed through direct elicitation surveys of the general population.(8)
Importantly, preference-based questionnaires can be used to generate utilities. Scores
from non-preference-based measures cannot be used directly to generate utilities; instead
they must be mapped using a statistical function.(8)
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Health state utility values (HSUVs) are commonly estimated by surveying patients, but
they can also be assessed by surveying experts (e.g., physicians) or the general
population. Importantly, each of these groups tend to value health states differently and
there are limitations with surveying each of these populations. While the general
population, comprised mainly of healthy individuals, tends to underestimate the utility of
diseased health states, patients who have experienced those states and have become
accustomed to them may place a higher value on those states.(9) Medical and surgical
experts may have greater knowledge of diseased states than the general population but
may be biased by their personal opinions of interventions and emotional connection with
patients.(15)

2.1.3. Existing CUAs in Breast Reconstruction
There are increasing numbers of cost-utility analyses examining breast reconstruction
options. Often these CUAs generate new utility values for the health states included in the
analysis. Although generating new health state utility values may allow for more accurate
assessment of the specific health state descriptions used in a model, repeatedly surveying
physicians and patients is time-consuming and costly. Given the need for costeffectiveness analyses in resource limited systems and the increasing rate of breast
reconstruction, understanding the existing published health state utility values and the
methods used to evaluate them is essential. Furthermore, developing strong estimates of
health state utility values is important to enhancing the external validity of CUA
models.(16)
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Thus, the purpose of this systematic review of utility measurements in breast
reconstruction was twofold. The first aim was to describe the metrics used to generate
utilities in the breast reconstruction literature and the second was to summarize the values
reported for common early and late postoperative complications for implant-based and
autologous breast reconstruction.

2.2. Methods
2.2.1. General
A systematic review was conducted to identify previously reported utility values and
quality of life outcomes generated through validated questionnaires in breast
reconstruction for either therapeutic or prophylactic mastectomy. The main objective was
to identify utility values for all health states relevant to breast reconstruction that can be
used in future cost-utility analyses.

2.2.2. Data Sources
An electronic search of English-language literature was performed of MEDLINE® and
Embase® databases for relevant articles published prior to November 2017. The search
strategy was designed with assistance from a librarian experienced in systematic reviews
(Table 2.2). In addition, reference lists of accepted papers and relevant review articles
were manually reviewed to identify additional articles.
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Table 2.2 Search Strategy
No.

Search

1

exp mammaplasty/ or (mammaplast$ or mammoplast$ or mastoplast$).mp. or (breast$ adj5
reconstruct$).mp. (16795)

2

exp "Costs and Cost Analysis"/ (225003)

3

(economic value of life or economics, medical or economics, pharmaceutical or models, economic
or markov chains or monte carlo method or uncertainty).sh. (68649)

4

economics.fs. (407092)

5

(quality of life or quality-adjusted life years).sh. (180352)

6

((econom$ or cost or costly or costing or costed or prices or pricing or discount or discounts or
discounted or discounting or budget$ or afford$ or pharmacoeconomic$ or pharmaco) adj1
economic$).ti,ab. (228130)

7

(decision adj1 (tree$ or analy$ or model$)).ti,ab. (15477)

8

((value or values or valuation) adj2 (money or monetary or life or lives)).ti,ab. (4665)

9

(QOL or QOLY or QOLYs or HRQOL or QALY or QALYs).ti,ab. or (quality$ adj2 life$).tw.
(243759)

10

((((quality adj1 life) or (willingness adj1 pay) or (quality adj1 adjusted life year$) or sensitivity) adj
analys?s) or quality adjusted life expectanc$).ti,ab. (27847)

11

economics.sh. (27494)

12

(Economic Impact or Economic Value or Pharmacoeconomics or Health Care Cost or Economic
Factors or Economics or Cost Analysis or Cost or Economic Analysis or Cost-Effectiveness or
Costs or "Quality of Life" or Health Care Cost or Cost Savings or Cost-Benefit Analysis or Hospital
Costs or Medical Costs or Quality-of-Life).mp. (892619)

13

exp Economic Evaluation/ or exp Pharmacoeconomics/ or Quality Adjusted Life Year.sh. or exp
Quality of Life/ (245192)

14

or/2-13 (1285636)

15

1 and 14 (1387)

16

limit 15 to english language (1285)

17

16 not (exp Animals/ not (Human/ and exp Animals/)) (1283)

18

meta analysis.mp,pt. or MEDLINE.tw. or systematic review.tw. (256532)

19

17 and 16 (1283)

20

limit 17 to "review articles" (161)

21

17 not 20 (1122)

22

19 or 21 (1283)

23

case report.ti. (213167)

24

22 not 23 (1281)
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2.2.3. Literature Screen
After removal of duplicates, all citations were screened in two stages by two independent
reviewers (Table 2.3). In the first stage, title and abstract were reviewed with the
following exclusion criteria: abstract only, non-English language articles, case reports,
letters, commentaries, non-systematic reviews, animal studies and in vitro studies. Since
it was anticipated that there would be few reports of utility values and that this may be
challenging to elicit from title and abstract alone, inclusion criteria were intentionally
made broad for the first stage of screening. Articles were included if they met the
following criteria: the study examined women undergoing breast reconstruction for either
therapeutic or prophylactic mastectomy and the study had the potential to report utility
values (i.e., was a possible economic analysis (i.e., referred to as cost-utility analysis,
cost-analysis, economic analysis, cost effectiveness analysis in title or abstract), reported
health state utility values (e.g., a report of independent utility generation, systematic
review or meta-analysis of utilities) or reported on quality of life using a validated tool
that could be used to generate utilities). If it was unclear whether a citation met the
inclusion criteria based on title and abstract alone, it was included for full-text review.
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Table 2.3 Systematic Review Inclusion and Exclusion Criteria
Inclusion Criteria

Exclusion Criteria

First Stage

Population
• breast reconstruction for
therapeutic or prophylactic
mastectomy)
Design
• economic analysis
• utility generation report or
validated patient-reported
outcome measure
• systematic review/metaanalysis

Incorrect population
Design
• conference abstract
• non-English language articles
• case reports
• letters
• commentaries
• non-systematic reviews
• laboratory (animal or in vitro)
studies

Second Stage

Design
• cost-utility analysis
• utility generation report

Design
• patient-reported outcome
measure without utility values
for specific postoperative health
states

In the second stage, the full text of articles that met inclusion criteria were reviewed in
addition to those studies for which a determination could not be made based on title and
abstract alone. A study was included after the second stage if it reported utilities (i.e. was
a cost-utility analysis or if it generated or reported utility values without a formal
economic analysis). Exclusion criteria at the second stage included incorrect study design
(i.e. did not report utilities), with the addition of cost-analysis, cost-effectiveness analysis,
cost-minimization analysis and cost-benefit analysis to the exclusion criteria. Studies that
reported validated health status measures but did not report utility values for specific
post-operative health states (e.g., complication states) were also excluded since the value
reported was an aggregate of successful, unsuccessful and complicated procedures.

2.2.4. Data Abstraction
Data was abstracted from included studies encompassing the following details: author,
journal, publication year, study design, study population (e.g., breast reconstruction,
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implant-based breast reconstruction, autologous reconstruction etc.), intervention (e.g.,
subtype of implant-based or autologous reconstruction, use of acellular dermal matrix
etc.), population and number of individuals surveyed to generate utility values, utility
metrics, health states, health state definitions and utility values reported.

2.2.5. Analysis
Included studies were discussed in a narrative fashion. There is a lack of consensus on
reporting methodology for HSUV studies; however, generic criteria have been published
by Papaioannou et al. and used in other systematic reviews of HSUVs.(16,17) Others
abide by the National Institute for Health and Clinical Excellence Guide to the Methods
of Technology Appraisal or CHEERS reporting guidelines.(18,19) Study quality was
described narratively with respect to these criteria. Studies that reported original utility
values and the number of individuals surveyed for utility generation were included in a
quantitative analysis in which weighted averages and standard deviations of reported
values were calculated with weights based on number of individuals surveyed (Appendix
1).(20) Since none of the articles reported confidence intervals or standard deviations for
the health state utility values a formal meta-analysis could not be performed. All statistics
were calculated using Microsoft® Excel®.
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2.3. Results
2.3.1. Search Results
The systematic review process is outlined in the PRISMA flow chart (Figure 2.1). The
literature search yielded 3060 records through MEDLINE and Embase of which 2279
remained after duplicates were removed. In addition to 4 records identified through crossreferencing, a total of 2283 records were screened. Of these, 2249 records were excluded
based on title and abstract. Full-text review was done for 219 citations and 200 were
excluded at this stage. Of the excluded citations, 17 were published in abstract format
only, 9 were cost-analyses, 3 were not specific to breast reconstruction (i.e., were studies
of women with breast cancer without specific assessment of reconstruction), 1 was a costeffectiveness analysis, 1 was a preference model that did not generate utilities and 169
used non-preference-weighted quality of life measures. Of the full-text articles reviewed
19 met inclusion criteria and only 10 of these published original utility values (i.e., not
obtained from a synthesis of the literature) that could be incorporated into a pooled
analysis.
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Figure 2.1 PRISMA Search Strategy Flow Diagram Utilities
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2.3.2. Study Design
Of the articles included following full-text review, 17 were cost-utility analyses and 2
were utility generation reports related to breast cancer and reconstruction (Table 2.4). Of
the cost-utility analyses, 9 assessed the relative costs and benefits of autologous
reconstruction, 6 assessed those of implant-based reconstruction and 4 did not specify the
reconstructive modality used but compared all reconstruction techniques to mastectomy
alone. Of the included studies, only one specified unilateral or bilateral reconstruction.
Further, only 5 studies specified timing of reconstruction as either immediate or delayed.
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Table 2.4 Characteristics of Included Studies
Author

Design

CUA Model
Population

Intervention

Utility Generation

Reconstruction Methods

Population

Utility
Metric

Number
Surveyed

Contribution to
Pooled Estimate

Chatterjee et
al. 2013(21)

CUA

Free
Laser-Assisted
Autologous
Indocyanine
Reconstruction Green
Angiography

Free Flap

Expert Opinion

TTO
VAS

10 Included

Grover et al.
2013(22)

CUA

Breast
Reconstruction
Reconstruction Method

Direct to implant,
expander-implant,
pedicled flap, free flap,
pedicled latissimus dorsi
flap with implant

Expert Opinion

VAS

9 Included

Hummelink et CUA
al. 2017(23)

Free
3D Planning
Autologous
with CT
Reconstruction Angiography

DIEP Flap

Literature
Review(21)

Ibrahim et al.
2015(24)

Utility
Report

Breast
N/A
Reconstruction

Breast reconstruction
without nipple
reconstruction

General
Population

Keskey et al.
2017(25)

CUA

Breast Cancer

With or without
reconstruction

Literature
Review(26–29)

Unilateral
Mastectomy vs.
Contralateral
Prophylactic
Mastectomy

2

N/A Included2

TTO
VAS
SG

103 Included

N/A Excluded

Values were obtained from literature but Hummelink et al. report a value that was not reported in source article so it was included to incorporate this additional
HSUV.
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Table 2.4 Characteristics of Included Studies
Author

Design

CUA Model
Population

Intervention

Utility Generation

Reconstruction Methods

Population

Utility
Metric

Number
Surveyed

Contribution to
Pooled Estimate

Krishnan et al. CUA
2014(30)

Implant-Based Acellular
Reconstruction Dermal Matrix
(ADM)

Expander-implant
Expert Opinion
immediate with or without
ADM

TTO
VAS

5 Included

Krishnan et al. CUA
2013(31)

Implant-Based Acellular
Reconstruction Dermal Matrix
(ADM) vs
Autologous
Dermal Flaps

Single-stage, implantbased immediate with
ADM or autologous
dermal flap

Expert Opinion

TTO
VAS

10 Included

Krishnan et al. CUA
2015(32)

Free
Reconstruction
Autologous
Method
Reconstruction

DIEP, muscle sparing
TRAM

Literature
Review(33)

Krishnan et al. CUA
2016(34)

Implant-Based Reconstruction
Reconstruction Method

Single-stage, expander
implant

Expert Opinion

Malin et al.
2002(35)

CUA

Breast Cancer

Unspecified

Literature
Review(36)

Matros et al.
2015(37)

CUA

Breast
Reconstruction
Reconstruction Method

3
4

N/A

Implant-based, autologous Patients
perforator flaps

N/A Excluded

VAS

N/A Excluded

BREASTQ

Utilities not reported by Krishnan et al. so were derived based on QALYs and health state duration for use in this study.
Utilities not reported and could not be derived based on reported health state information.
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Table 2.4 Characteristics of Included Studies
Author

Design

CUA Model
Population

Utility
Metric

Free
Preoperative CT Free flap
Autologous
Angiography
Reconstruction

Expert Opinion

TTO
VAS

Peasgood et al. Utility
2010(26)
Report

Breast Cancer

Literature
Review

Preminger et
al. 2008(39)

CUA

Breast
Reconstruction
Reconstruction Method

Implant-based, free TRAM Literature
Review,
Author
Assumption

Razdan et al.
2016(40)

CUA

LocallyAdvanced
Breast Cancer

Reconstruction
Method

Mastectomy alone,
immediate expanderimplant, delayed
autologous

Patients

Roberts et al.
2014(27)

CUA

Breast Cancer

Unilateral
Mastectomy vs.
Contralateral
Prophylactic
Mastectomy

Expander-implant

Literature
Review

N/A Excluded

Thoma et al.
2008(41)

CUA

Free
Reconstruction
Autologous
Method
Reconstruction

DIEP, SIEA

Literature
(Thoma et al.
2004)

N/A Excluded

Thoma et al.
2003(42)

CUA

Breast
Reconstruction
Reconstruction Method

Free TRAM, pedicled
TRAM

Expert Opinion

CUA

N/A

Reconstruction Methods

Unspecified

5

Number
Surveyed

Contribution to
Pooled Estimate

Population

Offodile et al.
2015(38)

Intervention

Utility Generation

Not Excluded
Reported
N/A Excluded
N/A Excluded

BREASTQ

VAS

343 Included5

33 Included

Included because utilities were reported for successful surgery. However, utilities were not reported for complication health states and could not be derived
based on reported health state information.
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Table 2.4 Characteristics of Included Studies
Author

Design

CUA Model
Population

Thoma et al.
2004(33)

CUA

Intervention

Breast
Reconstruction
Reconstruction Method

Utility Generation

Reconstruction Methods

Population

Utility
Metric

DIEP, free TRAM

Expert Opinion

VAS

37

Number
Surveyed

Contribution to
Pooled Estimate

32 Included
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2.3.3. Utility Generation
Utilities were generated through expert opinion surveys in 7 studies, through literature
review in 9 studies, through patient questionnaires in 2 studies and through a survey of
the general population in 1 study. Of the studies that generated utilities from expert
opinion, 4 administered time trade-off surveys or visual analogue scales to experts
depending on respondent familiarity with each tool while 4 administered visual analogue
scales alone. Only 1 study used standard gamble to generate utilities. Of the 2 articles that
surveyed patients to generate utilities, both used the BREAST-Q™, a validated, patientreported outcome measure which has been widely used.(43) Of the cost-utility analyses
that obtained utilities from the literature, 4 cited articles that generated utilities through
expert opinion (TTO or VAS),(23,32,35,38) one cited a value generated for an “absent
breast” health state using the Health and Activity Limitation Index(39) and the remainder
were unspecified.

2.3.4. Health States
Overall, the 19 included articles reported utility values for 35 distinct health states of
which 17 were related to breast reconstruction. However, definitions and durations of
health states varied by study and were inconsistently reported.

2.3.5. Utility Values
Only the 10 studies that generated original utility values were included in the pooled
estimates (Table 2.5). Successful surgery (i.e., without complications) was reported by 8
studies of which 4 studies reported utilities for multiple reconstructive techniques
resulting in 15 observations that contributed to the pooled estimate of 0.73 (95%CI 0.59-
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0.87). Successful autologous breast reconstruction had a higher average utility than
successful implant-based breast reconstruction. Complication states varied widely, with
total flap loss associated with the lowest utility (0.55 95%CI 0.40-0.71), which was worse
than the utility of mastectomy alone (0.60 95%CI 0.51-0.68). The utility for hematoma
(0.73 95%CI 0.59-0.87) approached that of successful surgery; however, this may be
explained by the higher utilities ascribed to the hematoma health state following
autologous reconstruction and the heavier weighting of these studies due to the greater
number of individuals surveyed for utility generation. Only 3 studies reported utility
values for explantation or capsular contracture health states.

Table 2.5 Pooled Health State Utility
Values
Health State

Mean Utilitya

SDa

Nb

Successful Breast Reconstruction

0.73

0.07

15 (21,22,30,31,33,34,40,42)

Implant-Based Breast Reconstruction

0.70

0.02

8

(22,30,31,34,40)

Autologous Breast Reconstruction

0.79

0.09

6

(21,22,33,40,42)

Total Flap Loss

0.55

0.07

6

(21,22,33,42)

Partial Flap Necrosis

0.72

0.02

8

(21,22,33,42)

Mastectomy Skin Necrosis

0.68

0.04

5

(21,30,31,42)

Hematoma

0.73

0.07

9

(21,30,31,33,34,42)

Infection

0.67

0.09

9

(21,22,30,31,34,42)

0.613

0.04

3

(30,31)

Capsular Contracture Grade III/IV

0.59

0.01

4

(30,34)

Revision

0.62

0.01

2

(34)

Nipple Deformity

0.89

N/A

3

(24)

Mastectomy Alone

0.60

0.04

2

(22,40)

Explantation

a Weighted

Referencesc

mean and SD, b Number of observations, c discrepancies between number of observations
and number of references is due to some citations reporting utilities for multiple reconstructive
techniques
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2.3.6. Methodological Quality
Overall, none of the studies met all of the requirements for the NICE reference case. Only
two studies surveyed the patient population for health status assessment. Both of these
used the BREAST-Q which is a validated condition-specific instrument.(37,40) However,
at the time of the analysis, the BREAST-Q did not have preference weighting available so
an average of the domain scores was used.(37,40) Neither of these studies report
demographic information for the respondents of the BREAST-Q so it is not possible to
know if the population sampled is representative of the population modelled. Likewise,
response rates and attrition are not reported. The CHEERS guidelines recommend
mapping for non-preference weighted instruments.(19) This was not performed in either
of the aforementioned cost-utility analyses. Further, the method by which the authors
generated utilities for specific health states based on the temporal association to survey
completion is unclear.

The remainder of the studies that generated unique utility values solicited expert opinion
using direct elicitation methods. This methodology is not recommended by either the
NICE guidelines or the CHEERs guidelines.

2.3.7. Heterogeneity
None of the articles reported confidence intervals for the health state utility values so
neither a formal meta-analysis nor a quantitative assessment of heterogeneity could be
performed.
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2.4. Discussion
Cost-utility analyses have an increasingly important role in resource planning given the
anticipated increased demand for health care services required by an aging
population.(44) To conduct high-quality analyses, the estimates of health state utility
values must reflect the perceptions of society at large.(45) In the breast reconstruction
literature, a number of CUAs have been conducted. These have used health state utility
values from a variety of sources. This systematic review attempted to catalogue the
methods of developing or choosing HSUVs in breast reconstruction-related CUAs and
aggregate published values into pooled estimates.

The results of this systematic review show that 50% of CUAs in breast reconstruction
select utility values previously reported in the literature, whether from single sources or
published meta-analyses. The remainder generated utility values independently, the
majority through direct elicitation surveys of physicians with only two studies obtaining
utility values by direct patient survey. There is considerable debate over the best group to
survey in health state utility value generation.(9,46) Proponents of patient valuation of
health states argue that patients know their own health and disease status best. However,
reported values may be higher due to the tendency of patients to adapt to their existing
health state over time. This may result in smaller than expected improvements in quality
of life with new interventions.(9) Others advocate for health status assessment by the
general population since economic analyses are meant to reflect values held by
individuals from diverse perspectives to be representative of a broader, societal
perspective.(47) Population-derived utilities are preferred for economic evaluations
designed to inform public policy decision-making since these utilities may be more
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representative of values held by the general population.

While use of generic health status measures is recommended in cost-utility analyses, none
of the included studies used such a measure, favouring instead direct-elicitation
techniques. Although there are many published studies that use generic health status
measures, these are limited by poor sensitivity to changes in health status in the postsurgical breast reconstruction population. In breast surgery, and breast reconstruction in
particular, many of the generic patient outcome measures are not sensitive to changes in
quality of life associated with early and late post-operative health states.(48) As such,
other scales have been developed to evaluate quality of life in these situations, such as the
BREAST-Q and the BRECON-31.(43,49) However, these measures do not yet have
preference-weighting and, therefore, are limited in their use with respect to utility
generation.

The majority of cost-utility analyses included in the quantitative analysis used direct
elicitation techniques, typically administered to medical experts. Although 3 studies did
report using time trade-off to generate utilities, 7 studies reported using visual analogue
scales for utility generation. Visual analogue scale is advantageous in that it is easy to
administer and understand. However, it is limited by multiple sources of bias and has
poor grounding in economic theory.(8,10) Recognition of these limitations is important
when borrowing values from the literature for utility estimates.

This systematic review has several strengths. It provides a summary of published costutility analyses in breast reconstruction with an emphasis on the method of utility
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generation. In addition, the quantitative analysis summarizes the published utilities as
weighted averages which can be used in future cost-utility analyses. Unfortunately, the
available studies included in the systematic review did not publish confidence intervals
for utility values. Therefore, a formal meta-analysis and quantitative assessment of
heterogeneity could not be performed. However, possible sources of heterogeneity among
reported utility values include variability in definition of health states, duration of health
states and method of health status assessment (i.e., direct versus indirect elicitation,
generic or diseases specific measures, preference-weighted or non-preference weighted
measures). Despite these limitations, this review contextualizes the existing literature on
economic analyses in breast reconstruction and highlights discrepancies between
commonly used methods for health status assessment and existing guidelines.

2.5. Conclusions
Utility values in breast reconstruction are variable and affected by surgical technique and
post-operative outcomes. The most commonly used methods of health status assessment
in the breast reconstruction literature are the VAS and TTO. This analysis can serve as a
reference for utilities and health states for future CUAs in breast reconstruction.
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3. Chapter 3: A Cost-Utility Analysis of Saline and Silicone Implants in Breast
Reconstruction

Overview
This chapter outlines considerations and parameters in designing cost-utilityanalyses. A cost-utility analysis examining saline and silicone implants in the context
of immediate, unilateral, implant-based breast reconstruction is described. Results
demonstrate silicone implants to be cost-effective despite higher baseline costs. This
analysis supports ongoing funding of silicone implants due to associated quality of
life improvements.6

3.1. Introduction
Breast reconstruction is a recognized component of the breast cancer treatment pathway.
As breast cancer mortality has decreased, management has increasingly focused on
interventions that result in improved quality of life in the survivorship period. There are
many approaches and adjuncts to breast reconstruction with diverse cost and
complication profiles.

In the context of breast reconstruction, adjuncts such as the use of CT angiography and
acellular dermal matrix have been demonstrated to be cost-effective in the American
health care system.(1,2) However, there remain a number of other parameters that are
unaccounted for in the existing cost-effectiveness literature. For instance, implant options

6

A portion of the work covered in Chapters 1 and 2 is included here as part of the Integrated Article
Format.
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are highly heterogeneous in terms of both cost and outcome profiles. One cross-sectional
survey of patients undergoing breast reconstruction showed higher quality of life among
patients who received silicone implants as compared to saline implants.(3) However,
saline implants can offer a significant cost savings. Further, rates of complications such
as capsular contracture and implant rupture may result in downstream costs to the patient
and health care system. These variations are not accounted for in the existing costeffectiveness literature; thus, it is important to delineate which is truly the cost-effective
option.

Cost-utility analysis facilitates integration of these outcomes, describing costs in
monetary units and outcomes in terms of health-related quality of life. This form of
economic analysis provides useful insights into efficient allocation of limited healthcare
resources. Although there are many factors that influence health-care spending decisions
including disease burden, social consensus, inequality and rule of rescue (i.e. perceived
duty to save lives in danger), cost-effectiveness analysis can be used to identify effective
treatments within resource constraints. (4)

Constructing a cost-effectiveness analysis requires identification of costs and effects for
all relevant stakeholders. To develop such a model, perspective (i.e., relevant
stakeholders) must be considered in addition to health states and associated probabilities,
utilities and costs.
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3.1.1. Considerations in Designing Cost-Utility Analyses
3.1.1.1. Perspective
The perspective of the cost-utility analysis determines which costs and outcomes should
be included. Decision-makers in health care include patients, clinics, hospitals, insurers
and public funders of health care. The societal perspective examines all costs and
outcomes relevant to society at large.(5) In practice, this can be challenging to measure as
documentation of patient costs requires patient enrollment and logging of incurred costs.
In the plastic surgery literature, the perspective of the hospital or third-party payer is
commonly adopted as these organizations bear the majority of costs relating to surgical
procedures. This is consistent with the recommendations from the Second Panel on CostEffectiveness in Health and Medicine which recommends the health care perspective as
the reference case.(6)

3.1.1.2. Health States, Probabilities and Utilities
Individual states of health are termed “health states.” These include individual well and
unwell conditions that collectively comprise a person’s health status. Health states
include concrete health outcomes, such as death, as well as more nuanced improvements
or deteriorations such as recovery of extremity function, ability to walk or chronic
pain.(7) In breast reconstruction, health states are related to technique and outcome. For
instance, abdominal morbidity can be associated with the use of abdominal-based flaps
while capsular contracture can occur after implant insertion. To determine the net costeffectiveness of different types of implants in breast reconstruction, all relevant health
states must be identified in addition to the associated probabilities, costs and quality of
life of each health state.

53

Chapter 3

3.1.1.3. Costs
There are varying levels of precision in estimating costs incurred by hospitals (Table 3.1).
Types of costs can be broken down into direct and indirect costs. Direct costs include
costs related to patient care (e.g., nursing, medications, investigations, etc.). Indirect costs
are those not directly related to patient care but that are nonetheless required to support
the patient, hospital, organization (e.g., health records, administration, maintenance,
patient out-of-pocket costs etc.). Costs can be calculated through multiple approaches.
The most accurate method of costing is micro-costing which accounts for all resources
used (e.g., medications, laboratory tests, length of stay in a particular ward, etc.).(8)
Unfortunately, it is challenging to do this outside of a prospective clinical study whereby
costs incurred can be tracked reliably. Average daily costs are the least accurate in which
total cost to the hospital per day is averaged over all categories of patients.(8) This
method does not allow for differentiation between patients that use more services than
others, such as patients in an intensive care unit as compared to those on low-acuity
wards. Other approaches include calculating average costs for case-mix groups, diseasespecific per diem costs and generic per diem costs. These are ultimately influenced by
how specifically cases and diseases are defined (e.g., patients undergoing mastectomy
with immediate reconstruction versus patients undergoing oncologic surgery in general).
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Table 3.1 Costing Methods
Method

Description

Micro-costing

All resources used are estimated and the costs for each are summed.

Case-mix costing

Patients are divided into clinically-meaningful groups based on type of case
and length of stay.

Per diem costing

Total resource use and expenditure are divided by number of days of
service provided to generate average daily cost.

3.1.2. Rationale and Hypothesis
Given the increasing rate of implant-based reconstruction it is essential to delineate the
cost-effectiveness of alternative implant-based treatments. The cost-effectiveness of
different implant types has not yet been analyzed; however, saline and silicone implants
vary in complication rates, costs and associated quality of life. This study examined the
cost-utility of saline and silicone implants in the context of immediate, unilateral,
implant-based breast reconstruction.

3.2. Methods
3.2.1. Perspective
The perspective of a third-party payer was adopted for this analysis, specifically the
Ontario Ministry of Health and Long-Term Care (MOHLTC). Relevant costs included
operating room expenses, clinic costs and physician costs. Home care costs were not
accounted for in this analysis. It was not possible to obtain the cost to the patient in terms
of productivity losses and out-of-pocket expenses since secondary data were used for this
analysis. As a result, a societal perspective was not considered.
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3.2.2. Population
The population was assumed to be women with stage I or II breast cancer seeking
unilateral mastectomy with implant-based reconstruction in the immediate setting. The
age of the cohort was assumed to be 52.5 years based on average age at diagnosis of
breast cancer in Canada.(9) Life-expectancy was assumed to be 83.9 years, derived from
Canadian census data, since life-expectancy of stage I and II breast cancer survivors
approaches that of age-matched controls.(10,11)

3.2.3. Time Horizon
The time horizon for the analysis was assumed to be 31.4 years based on difference
between life-expectancy and age at diagnosis.

3.2.4. Health States
A review of the surgical literature was conducted to identify relevant complications
associated with implant type following implant-based breast reconstruction. These
complications included capsular contracture, implant rupture, unplanned revision and
explantation. Complications related to implant use but unrelated to implant filler type
(e.g., breast-implant associated anaplastic large cell lymphoma, hematoma, etc.) were not
included. The complications were defined as distinct health states (Table 3.2) with
associated probabilities, costs and utilities. Assumptions regarding duration of health
states and treatment course were based on institutional practice patterns.
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Table 3.2 Health State Descriptions
Health State

Description and Assumptions

Successful Surgery

Initial pre-surgical consultation with plastic surgeon, followed by outpatient
surgery. Surgery assumed to be 2.5 h duration. Patient returns for follow-up visit
at 1 week, 2 weeks, 6 weeks and 6 months.

Capsular Contracture
Grade III/IV

Patient develops significant capsular contracture requiring surgical capsulotomy
as outpatient. Patient keeps original implants. In addition to costs of successful
surgery, patient requires repeat clinic visit to discuss problem prior to surgical
intervention. Surgery assumed to be 2 h duration. Patient returns for follow-up
visit at 2 weeks, 6 weeks and 6 months. Duration of health state assumed to be 1
year followed by a return to successful surgery health state.

Explantation

Patient develops problem requiring or preferring implant removal without
replacement. In addition to costs of successful surgery, patient requires repeat
clinic visit to discuss problem prior to surgical intervention. Surgery assumed to
be 1 h duration as outpatient. Patient returns for follow-up visit at 2 weeks, 6
weeks and 6 months. Duration of health state assumed to be 1 year followed by
return to mastectomy defect health state.

Unplanned Revision

Patient develops clinical problem related to implant-based reconstruction. In
addition to costs of successful surgery, patient requires repeat clinic visit to
discuss problem prior to surgical intervention. Surgery assumed to be 2 h duration
as outpatient. Patient returns for follow-up visit at 2 weeks, 6 weeks and 6
months. Duration of health state assumed to be 1 year followed by return to
successful surgery health state.

Saline Implant
Rupture

Patient develops clinically evident deflation seeking implant replacement. In
addition to costs of successful surgery, patient requires repeat clinic visit to
discuss problem prior to surgical intervention. Surgery assumed to be 2 h duration
as outpatient. Patient returns for follow-up visit at 2 weeks, 6 weeks and 6
months. Duration of health state assumed to be 1 year followed by return to
successful surgery health state.

Silicone Implant
Rupture

Concern for rupture triggers presentation to plastic surgeon. Workup includes
MRI followed by surgery for implant exchange. In addition to costs of successful
surgery, patient requires repeat clinic visit to discuss problem prior to surgical
intervention. Surgery assumed to be 2.5 h duration as outpatient. Patient returns
for follow-up visit at 2 weeks, 6 weeks and 6 months. Duration of health state
assumed to be 1 year followed by return to successful surgery health state.

3.2.5. Costs
The costs for implant-based reconstruction were based on values obtained from the CaseCosting Centre at St. Joseph’s Health Care (SJHC) London. SJHC is a predominantly
ambulatory care hospital with outpatient surgical facilities and an inpatient surgical ward.
The Surgical Case Costing Centre at SJHC performs micro-costing for surgical
procedures that are designated as Quality-Based Procedures by the Ontario MOHLTC.
Quality-Based Procedures reflect clusters of clinically-related patients, diagnoses and
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treatments that are used to direct improvements in health services and can be refined
based on Canadian Classification of Health Intervention (CCI) codes.(12) Breast cancer
surgeries, including both ablation and reconstruction, have been identified as QualityBased Procedures since 2016.(13) CCI codes were used to identify relevant procedures
(Table 3.3) The cost estimates from the Case Costing Centre include all direct and
indirect costs incurred during day surgery except physician costs. This includes operating
room supplies, nursing, administrative overhead, pharmaceuticals, imaging and
laboratory investigations for operating room supplies including implants, and acellular
dermal matrix (Appendix 2). Overhead and operating room labour is estimated based on
staffing and converted into a cost per minute of operating room time. The average cost of
relevant CCI codes was used as the base cost for complication health states. Billing codes
under the “Schedule of Benefits: Physician Services Under the Health Insurance Act”
were used to estimate physician costs (Table 3.4).(14)

Costs for implants were obtained from the Healthcare Materials Management Service
(HMMS). HMMS works with both SJHC and London Health Sciences Centre (LHSC) to
facilitate purchasing and inventory management through competitive bidding agreements.
Costs for individual implant models are confidential and protected under the competitive
bidding agreements so average prices of saline and silicone implants were used
(Appendix 3).

Costs for breast MRIs were obtained from the institutional radiology department. Breast
MRI procedural costs, including supplies, technologists and storage, are $130 per exam.
The cost of the MRI machine is approximately $2.5 million which is depreciated over 7
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years at SJHC. Costs for radiologist reads of an MRI were obtained from the “Schedule
of Benefits”. All costs were reported in 2017 Canadian Dollars (Appendix 4, Appendix
5).

Table 3.3 CCI Codes for Implant-Based Breast Reconstruction
CCI Code

Description

1YM90LAPM

Excision total with reconstruction, breast simple mastectomy with no node dissection
without tissue with implantation of breast prosthesis
Excision total with reconstruction, breast simple mastectomy with no node dissection
using local flap with implantation of breast prosthesis
Excision total with reconstruction, breast using homograft with implantation of breast
prosthesis
Excision total with reconstruction, breast simple mastectomy with no node dissection
without tissue with implantation of prosthesis and expander
Excision total with reconstruction, breast simple mastectomy with no node dissection
using local flap with implantation of prosthesis and expander
Excision total with reconstruction, breast simple mastectomy with no node dissection
without tissue with implantation of tissue expander
Excision total with reconstruction, breast using local flap with implantation of tissue
expander
Excision total with reconstruction, breast using homograft with implantation of tissue
expander
Excision radical with reconstruction, breast modified or NOS using local flap with
implantation of breast prosthesis
Excision radical with reconstruction, breast modified or NOS using homograft with
implantation of.breast prosthesis
Excision radical with reconstruction, breast modified or NOS using local flap with
implantation of prosthesis and expander
Excision radical with reconstruction, breast modified or NOS using local flap with
implantation of tissue expander
Excision radical with reconstruction, breast modified or NOS using homograft with
implantation of tissue expander
Excision radical with reconstruction, breast extended [Urban] using local flap with
implantation of breast prosthesis
Excision radical with reconstruction, breast extended.[Urban] using homograft with
implantation of breast prosthesis
Excision radical with reconstruction, breast extended [Urban] using local flap with
implantation of prosthesis and expander
Excision radical with reconstruction, breast extended [Urban] using local flap with
implantation of tissue expander
Excision radical with reconstruction, breast extended.[Urban] using homograft with
implantation of tissue expander
Excision radical with reconstruction, breast super [Wangensteen] using local flap with
implantation of breast prosthesis
Excision radical with reconstruction, breast super [Wangensteen] using homograft with
implantation of breast prosthesis
Excision radical with reconstruction, breast super [Wangensteen] using local flap with
implantation of prosthesis and expander
Excision radical with reconstruction, breast super [Wangensteen] using local flap with
implantation of tissue expander

1YM90LAPME
1YM90LAPMK
1YM90LAQF
1YM90LAQFE
1YM90LATP
1YM90LATPE
1YM90LATPK
1YM92LAPME
1YM92LAPMK
1YM92LAQFE
1YM92LATPE
1YM92LATPK
1YM92TRPME
1YM92TRPMK
1YM92TRQFE
1YM92TRTPE
1YM92TRTPK
1YM92WPPME
1YM92WPPMK
1YM92WPQFE
1YM92WPTPE
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1YM92WPTPK Excision radical with reconstruction, breast super [Wangensteen] using homograft with
implantation of tissue expander
1YM90LAPM Excision total with reconstruction, breast simple mastectomy with no node dissection
without tissue with implantation of breast prosthesis
1YM91LAXXQ Excision radical, breast using combined sources of tissue [e.g., local flap and tissue
expander] modified or NOS
1YM91LAPM Excision radical, breast with implantation of breast prosthesis modified or NOS
1YM91LATP
Excision (modified) radical, breast with implantation of tissue expander
1YM88LAPM Excision partial with reconstruction, breast without tissue with implantation of prosthesis
1YM88LAPME Excision partial with reconstruction, breast with local flap with implantation of
prosthesis
1YM88LAPMK Excision partial with reconstruction, breast using homograft with implantation of
prosthesis
1YM88LAQF Excision partial with reconstruction, breast without tissue with implantation of prosthesis
and expander
1YM88LAQFE Excision partial with reconstruction, breast with local flap with implantation of prosthesis
and expander
1YM88LATP
Excision partial with reconstruction, breast without tissue with implantation of tissue
expander
1YM88LATPE Excision partial with reconstruction, breast with local flap with tissue expander
1YM88LATPK Excision partial with reconstruction, breast using homograft with implantation of tissue
expander
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Table 3.4 OHIP Billing Codes for Implant-Based Breast Reconstruction and Related Procedures
Code

Description

R119
R114
Z135
Z142
Z182
A085
A935
A086
A083
A084
X446

Breast mound creation by prosthesis as sole procedure
Revision of breast mound
Open capsulotomy with or without replacement of breast prosthesis
Removal of breast prosthesis
Breast capsulectomy
Consultation
Special surgical consultation
Repeat consultation
Specific assessment
Partial assessment
Breast MRI unilateral or bilateral multi-slice sequence

3.2.6. Probabilities
The probabilities associated with clinically relevant health states for implant-based breast
reconstruction with saline and silicone implants were obtained from a review of the
literature. An electronic search of English-language articles published prior to November
2017 was conducted. The search strategy was developed with assistance from a librarian
familiar with systematic reviews. The search strategy included terms relevant to implantbased breast reconstruction (Table 3.5). Results were screened for articles that examined
saline versus silicone implants in the context of implant-based reconstruction and
reported post-operative outcomes (Table 3.6). Citations were screened in two-stages. The
first stage involved a review of title and abstract. Articles that met inclusion criteria or for
which a determination could not be made were reviewed in the second stage in full text.
Parameter estimates were extracted from relevant articles and weighted averages were
calculated as appropriate.
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Table 3.5 Search Strategy
No.

Search

1 Breast Implantation/ or Breast Implants/ or (breast$ and (implant$ or prosthes$)).mp. (13358)
2 exp *Breast/su and exp *"Prostheses and Implants"/ (846)
3 or/1-2 (13374)
4 follow-up studies.sh. or (follow-up or followup or follow$).mp. (3502738)
5 3 and 4 (4030)
6 Reoperation/ or (revision$ or re-vision$ or (repeat$ adj3 surg$) or re-operat$ or reoperat$ or reconstruct$ or reconstruct$ or mastectom$ or mammectom$).mp. or exp prosthesis failure/ or
prosthesis-related infections/ or Implant Capsular Contracture/ or contracture$.mp. or exp treatment
outcome/ or complication$.mp. or outcome$.tw. or (ae or co).fs. or incidence.sh. or incidence$.tw. or
infect$.tw. (7255071)
7 Comparative Study/ or (vs$1 or vs or versus or compar$).tw. or ((silicone$ or textured$ or round)
and saline$).tw. or ((augmentation$ and ((revision$ or re-vision$) adj3 augmentation$)) or ((reconstruct$ or reconstruct$) and ((revision$ or re-vision$) adj3 reconstruct$))).tw. or (different$ adj2
types$).tw. or (two adj2 different$).tw. or ((textured or rough) and smooth$).tw. (6570586)
8 3 and 4 and 6 and 7 (1351)
9 *Breast Implantation/ or *Breast Implants/ or (breast$.tw. and (implant$ or prosthes$).ti.) (6140)
10 (re-construct$ or reconstruct$ or mastectom$ or mammectom$).tw. (282471)
11 7 and 9 and 10 (774)
12 8 or 11 (1685)
13 limit 12 to english language (1582)
14 13 not (exp Animals/ not (Human/ and exp Animals/)) (1537)
15 meta analysis.mp
16 14 and 15 (80)
17 limit 14 to "review articles" (121)
18 14 not 17 (1416)
19 16 or 18 (1475)
20 case report.ti. (213628)
21 19 not 20 (1467)
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Table 3.6 Systematic Review Inclusion and Exclusion Criteria
Inclusion Criteria

Exclusion Criteria

Population
Population
• implant-based breast reconstruction for
• autologous reconstruction
therapeutic or prophylactic
• reconstruction for non-oncologic entities (e.g.,
mastectomy)
congenital/traumatic breast anomalies)
Design
Design
• RCT, retrospective or prospective
• conference abstract
cohort study, observational study
• non-English language articles
• exposure: comparisons of saline versus
• case reports
silicone implants
• letters
• outcomes: postoperative complications
• commentaries
(immediate and delayed)
• non-systematic reviews
• laboratory (animal or in vitro) studies

The systematic review yielded 2185 records. The 1267 records which remained after
duplicates were removed were screened by title and abstract. Of these, 23 records were
reviewed in full text (Figure 3.1). There was a paucity of studies directly comparing
saline versus silicone implants in implant-based breast reconstruction. Due to
heterogeneity in study design and reported outcomes, none of the studies reported data
useful for meta-analysis. Overall, there were a large number of retrospective and
prospective non-randomized studies examining saline and silicone implants. However,
few undertook direct comparisons between saline and silicone implants. At present, the
best prospective data for saline and silicone implants comes from the post-market
approval analyses of saline implants and silicone implant Core studies.(15–18) The
silicone implant Core studies examined the fourth and fifth generation silicone implants
most commonly used today. Ultimately, parameter estimates for this analysis were
extracted from relevant Core studies and post-market approval data.
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Figure 3.1 PRISMA Search Strategy Flow Diagram Probability Estimates
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3.2.7. Utilities
Utility values for clinically relevant health states were derived from a systematic review
of the literature (Chapter 2). An electronic search of English-language articles published
prior to November 2017 was conducted. The search strategy was conducted with
assistance from a librarian familiar with systematic reviews. The search strategy included
terms relevant to implant-based breast reconstruction and economic analysis (Table 2.2).
Articles which generated unique utility values and reported number of individuals
surveyed were included in a quantitative synthesis in which pooled estimates were
generated. Weighted averages and standard deviations were calculated with weights
based on study size. Additional values were generated from published quality of life data
as appropriate.(3)

Utilities were converted into quality adjusted life years by multiplying the utility by the
duration of the health state and adding it to remaining life years multiplied by the utility
of a successful surgery. The average age of women in the cohort was assumed to be 52.5
based on average age at diagnosis of breast cancer.(9) Life-expectancy was assumed to be
83.9 years, derived from Canadian census data since life-expectancy of stage I and II
breast cancer survivors approaches that of age-matched controls.(10,11)

3.2.8. Analysis
A decision tree model was designed using TreeAge Pro 2017 © (Figure 3.1). Costs,
QALYs and probabilities of each health state were incorporated into the model (Table
3.7). Expected values for costs and outcomes were derived by the roll-back method and
summed to generate the expected cost and utility of breast reconstruction with saline or
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silicone implants. Costs and utilities were discounted at a rate of 3 percent per year. Onset
of complications was assumed to be 10 years based on follow-up data from silicone
implant Core studies and post-market approval data for saline implants.(15–18) The
incremental cost-utility ratio (ICUR) was calculated using the following formula:
!"#$ =

&'()*+), *./+ .0 /121*.3) 14(253+ − &'()*+), *./+ .0 /5213) 14(253+
&'()*+), 789: .0 /121*.3) 14(253+ − &'()*+), 789: .0 /5213) 14(253+

An intervention is considered cost-effective if the ICUR is less than the willingness-topay (WTP) threshold for an additional quality-adjusted life year. The willingness-to-pay
threshold was set at $50,000/QALY, as a conservative boundary and to be consistent with
current literature.(19)

One-way sensitivity analysis was performed to determine if the baseline decision analysis
was robust by varying the complication rate of saline implants from 0 to 1 in increments
of 0.02 and observing how this affected the ICUR. Other sensitivity analyses were
conducted to examine different rates of capsular contracture, implant rupture and
discounting rates.
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Table 3.7 Health State Costs, Probabilities and Utilities
Health State

Cost SJHC ($) Cost LHSC
($)

Probability
(citation)

Range1

Utility2
(citation)

Range

Duration
(Years)

QALYs3

6988.12

0.472 (15,16)

(0.285, 0.545)

0.77 (3)

(0.544,
0.933)

31.4

16.47

(0.092, 0.067)

0.59

(0.58, 0.6)

0.5

16.34

Silicone
Successful Surgery

5788.12

Complication States

0.528

Capsular Contracture
Grade III/IV

5946.71

4747.51

0.075 (15,16)

Explantation

5750.66

4551.46

0.136 (15)

0.61

(0.585,
0.655)

0.5

14.34

Unplanned Revision

5981.06

47.81.86

0.260 (15)

0.62

(0.61, 0.62)

0.5

16.36

Implant Rupture

6948.81

5675.46

0.057 (15,16)

(0.076, 0.049)

0.624

0.5

16.36

6765.52

5468.32

0.446 (17,18)

(0.44, 0.454)

0.72 (3)

(0.476,
0.923)

31.4

15.40

(0.127, 0.161)

0.59

(0.58, 0.6)

0.5

15.31

Saline
Successful Surgery
Complication States

0.554

Capsular Contracture
Grade III/IV

5946.71

4747.51

0.146 (17,18)

Explantation

5750.66

4781.86

0.079 (17)

0.61

(0.585,
0.655)

0.5

13.90

Unplanned Revision

5981.06

4551.46

0.226 (17)

0.62

(0.61, 0.62)

0.5

15.33

Implant Rupture
6461.71
5164.51
0.103 (17,18) (0.099, 0.105) 0.615
0.5
15.33
2
refers to highest and lowest reported values for a probability or utility. All utilities were generated from a systematic review of published utilities
(Chapter 2, Table 2.5) except those for successful surgery which were generated from published BREAST-Q data.(3) 3QALYs discounted at 3% per year. 4Utility
for implant rupture silicone adapted from unplanned revision since rupture is typically asymptomatic. 5Utility for implant rupture saline adapted from
explantation since deflation results in temporary explantation-like deformity
1Range
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Figure 3.2 Decision model used in cost-utility analysis for saline versus silicone implants in breast reconstruction (SJHC Data).
Probabilities displayed below branches. Costs and QALYs displayed to the right of terminal branches.
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3.3. Results
The cost-utility analysis revealed an incremental cost increase of $103.63 associated with
the use of silicone implants and a gain of 0.89 QALYs. The incremental cost-utility ratio
was $116.51 per QALY for silicone implants (Table 3.8) . Overall, silicone implants are
cost-effective as the ICUR was less than the WTP threshold. The analysis was also
repeated with cost data from London Health Sciences Centre (LHSC) (Appendix 5,
Appendix 6), a partner organization in HMMS. Despite a slightly lower base cost for
saline implants at LHSC, silicone implants were still cost-effective within a WTP
threshold of $50,000/QALY (Table 3.8). Sensitivity analyses were conducted with
discounting rates of 1.5% and 5%. When discounted at a rate of 1.5%, the ICUR was
$79.14.
Table 3.8 Results of Cost-Utility Analysis of Implant Type in Breast Reconstruction
Strategy
Cost
Incremental
Effect
Incremental
ICUR
($)
Cost ($)
(QALYs)
Effect
($/QALY)
(QALYs)
3% Discounting Rate
SJHC
Saline Implant
9250.52
15.25
Silicone Implant

9354.15

103.63

16.14

0.89

116.51

LHSC
Saline Implant
Silicone Implant

7451.51
7679.83

228.33

15.25
16.14

0.89

256.71

1.5% Discounting Rate
SJHC
Saline Implant
9643.18
Silicone Implant
9728.01

84.83

18.71
19.79

1.07

79.14

5% Discounting Rate
SJHC
Saline Implant
8815.77
Silicone Implant
8940.21

124.44

11.99
12.70

0.72

173.74
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One-way sensitivity analysis of SJHC data revealed that silicone implants were costeffective at any complication rate associated with saline implants using a WTP threshold
of $50,000/QALY. Saline implants became more costly and less effective than silicone
implants at a complication rate of 0.58. (Figure 3.3). The sensitivity analysis was repeated
for the LHSC data with similar results. Saline implants were more costly and less
effective than silicone implants at a complication rate of 0.62 (Figure 3.4). One-way
sensitivity analysis varying the probability of saline implant rupture demonstrated that
silicone implants were cost-effective at any rate of saline implant rupture (SJHC Data).
Silicone implants were more effective and less costly when the probability of saline
implant rupture reached 0.66 (Figure 3.5). One-way sensitivity analysis was also
performed varying the probability of saline implant capsular contracture. This
demonstrated that silicone implants were cost-effective at any probability of saline
capsular contracture within the $50,000/QALY WTP threshold (Figure 3.6). However,
with increasing probability of capsular contracture, the ICUR for silicone implants
increased. This was because capsular contracture was a less costly health state compared
to two of the remaining complication health states (i.e., implant rupture and unplanned
revision). This sensitivity analysis was repeated varying the rate of silicone implant
capsular contracture. With increasing probability of capsular contracture, the ICUR for
silicone implants decreased consistent with the capsular contracture health state being
less costly than the remaining complication health states as described above. Silicone
implants were cost-effective at any rate of capsular contracture within a WTP threshold
of $50,000/QALY (Figure 3.7).
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Figure 3.3 One-way sensitivity analysis varying complication rate of saline implants (SJHC Data).
A. Incremental cost of saline and saline implants as a function of saline implant complication rate. B. Incremental effect of saline and
silicone implants as a function of saline implant complication rate. Up to a saline implant complication rate of 0.58 it is more effective
but also more costly to use silicone implants. After this it is cheaper and more effective to use silicone implants.
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Figure 3.4 One-way sensitivity analysis varying complication rate of saline implants (LHSC Data).
A. Incremental cost of saline and saline implants as a function of saline implant complication rate. B. Incremental effect of saline and
silicone implants as a function of saline implant complication rate. Up to a saline implant complication rate of 0.62 it is more effective
but also more costly to use silicone implants. After this it is cheaper and more effective to use silicone implants.
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Figure 3.5 One-way sensitivity analysis varying probability saline implant rupture (SJHC Data).
A. Incremental cost of saline and saline implants as a function of saline implant rupture rate. B. Incremental effect of saline and
silicone implants as a function of saline implant rupture rate. Up to a saline implant rupture rate of 0.66 it is more effective but also
more costly to use silicone implants. After this it is cheaper and more effective to use silicone implants.
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Figure 3.6 One-way sensitivity analysis varying probability of saline implant capsular contracture (SJHC Data).
A. Incremental cost of saline and saline implants as a function of saline implant capsular contracture rate. B. Incremental effect of
saline and silicone implants as a function of saline implant capsular contracture rate. As saline implant capsular contracture rate
increases the incremental cost of silicone implants increases and incremental effect decreases. This was because capsular contracture
was a less costly health state compared to two of the remaining complication health states (i.e., implant rupture and unplanned
revision).
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Figure 3.7 One-way sensitivity analysis varying probability of silicone implant capsular contracture (SJHC Data).
A. Incremental cost of saline and saline implants as a function of silicone implant capsular contracture rate. B. Incremental effect of
saline and silicone implants as a function of silicone implant capsular contracture rate. As silicone implant capsular contracture rate
increases the incremental cost of silicone implants decreases and incremental effect increases. This was because capsular contracture
was a less costly health state compared to two of the remaining complication health states (i.e., implant rupture and unplanned
revision).

75

Chapter 3
3.4. Discussion
Breast reconstruction is becoming increasingly common following both therapeutic and
prophylactic mastectomy and is important to quality of life in the survivorship period.
Identifying cost-savings is imperative in resource-limited systems. However, more costly
interventions must be contextualized in terms of their associated quality of life
improvement.

This cost-utility analysis compares the two most commonly used types of implants in
North America, saline-filled and silicone gel implants, in the context of breast
reconstruction. The results suggest that both saline-filled and silicone implants are costeffective within a willingness-to-pay threshold of $50,000/QALY. Further, increasing
saline-filled implant complication rates beyond 0.58 in a one-way sensitivity analysis
results in silicone implants being less costly and more effective (i.e. dominant strategy).

This model focused on the unilateral, immediate, one-stage implant-based breast
reconstruction population. Women included in the model were assumed to have early
stage (I or II) breast cancer as these women are eligible for immediate breast
reconstruction. Typically, women with more advanced breast cancer (locally advanced or
metastatic) are not eligible for this form of reconstruction due to higher risk of
recurrence, anticipated requirement for adjuvant radiation and altered life-expectancy.
Further, women with early stage breast reconstruction who survive the first three years
following diagnosis return to life-expectancy of age-matched controls.(11) For this
reason, the general population life-expectancy was used in this analysis. This analysis
focused on unilateral reconstruction. Although contralateral prophylactic mastectomy is
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increasing, unilateral mastectomy continues to be more common. Although a lower
percentage of women undergoing unilateral mastectomy undergo reconstruction (27.4%
versus 56% bilateral), this still constitutes a greater total number of unilateral
reconstructions than bilateral reconstructions.(20) Patients undergoing unilateral implantbased reconstruction are different from those undergoing bilateral reconstructions in that
patients undergoing contralateral prophylactic mastectomy tend to be younger, of
Caucasian race, with private insurance coverage and family histories of breast and
ovarian cancer.(21–23) They are also different in terms of expected outcomes such as
symmetry and cosmesis which tend to be better with bilateral reconstructions. Because of
this, the results of this analysis may not be generalizable to the bilateral reconstruction
population. However, implant filler is not expected to confer a difference in outcomes
between unilateral and bilateral reconstructions. This analysis also focused on immediate
reconstruction since more women are opting for immediate reconstruction in both Canada
and the United States.(20,24)

The perspective used for this analysis was that of the Ministry of Health and Long-Term
Care (MOHLTC). Costs relevant to the MOHLTC include operating room costs, surgeon
and anesthetist billing costs, clinic costs and community care costs. Operating room costs
were obtained through the institutional case costing centre. The “Schedule of Benefits for
Physician Services under the Health Insurance Act” was used the surgeon, anesthetist and
radiologist billing codes for both operating room and clinic-related costs.(14) Patients
who undergo implant-based breast reconstruction often require community care for drains
for approximately one week. These costs were not included in this analysis and as such
this constitutes a gap in the costs from the MOHLTC perspective.
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Health states were defined based on a review of the literature. The most common
complications associated with implant filler type were used to determine relevant health
states. Psychological impacts of different implant filler options were assumed to be
accounted for by the health state utility value. Duration of each health state was an
approximation based on surgeon practice patterns. Given typical wait times for repeat
consultation and surgery, these were felt to be conservative estimates. Certain elements of
the health state definitions, including surgery duration, influenced costs, such as estimates
of anesthesiology billing since these billing codes are based on time units.

This model used utilities obtained from the literature. Although this analysis focused on
women undergoing unilateral reconstruction, none of the included utilities specified
whether utilities were specific to unilateral or bilateral reconstruction. Conversely, the
majority of utilities reported in the context of implant-based reconstruction examined the
immediate implant-based reconstruction scenario.(1,25–28) This suggests that the utilities
used here may prevent the results of this analysis from being extrapolated to delayed
reconstruction. It is challenging to know how the utilities used would be influenced by
unilateral or bilateral reconstruction. Bilateral reconstruction is associated with improved
symmetry compared to unilateral reconstruction. However, the population of individuals
undergoing bilateral mastectomy and reconstruction may be different from the unilateral
population in terms of their expectations of post-operative outcomes. Nonetheless, it is
not expected that implant filler would influence quality of life based on unilateral versus
bilateral reconstruction.
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Varying complication rates influence the relative cost-effectiveness of saline and silicone
implants. This analysis is unfortunately limited by a lack of high-quality data directly
comparing saline and silicone implants. A recent Cochrane systematic review was
published on this topic concluding that it was not possible to delineate differences
between saline and silicone implants based on existing trials.(29) However, the review
was limited in several ways. Firstly, there are few randomized controlled trials (RCTs)
directly comparing saline and silicone implants. Secondly, the RCTs that are published
do not reflect the currently available implants, particularly with regard to the later
generations of silicone implants. Some of the largest prospective studies of saline and
silicone implants come from the Core Studies required for FDA approval. The Core
Studies are industry-funded, prospective, non-randomized studies in which women
receiving breast implants for augmentation or reconstruction were followed for 10 years.
Although there are myriad retrospective and prospective cohort studies of women
undergoing implant-based breast reconstruction, few provide independent analysis of
complication rates based on implant type.

Costs for this analysis were obtained from multiple sources of secondary data. Estimates
of direct and indirect costs of implant-based breast reconstruction were obtained through
the institutional Case-Costing Centre. This Centre does case-costing for QBPs in breast
reconstruction through micro-costing initiatives which have the potential to provide
accurate cost estimates of all resources used. These costs were ultimately aggregated to
provide average costs for patients undergoing implant-based breast reconstruction. Costs
for individual implant models are confidential and protected under the competitive
bidding agreements so average prices of saline and silicone implants available through
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HMMS were used. Although these costs may be lower than catalogue prices, they may be
a better reflection of implant costs incurred at centres with competitive bidding
agreements. However, because local costs were used here, this model may not be
generalizable to institutions without competitive bidding agreements or other provinces
with different fee structures for physician and procedure billing.

A decision-tree model was used to perform the cost-utility analysis. Other types of
models, such as Markov models, can account for repeated events in time. Use of a
Markov model requires probability estimates of successful surgery, complications as well
as movement between each well and unwell health state. These models have the
advantage of being able to account for repeated events in time, such as requiring multiple
revision surgeries or developing multiple complications. Although conceptually it is
understood that certain events predispose to further complications (e.g., infection leading
to higher risk of capsular contracture), transition probabilities are not available in the
current literature. Given the limitations of the literature, the most appropriate model was
the decision-tree. Deterministic sensitivity analyses were conducted to determine if the
baseline decision analysis was robust. Varying overall probability of complications in
addition to probability of implant rupture and capsular contracture demonstrated that
silicone implants remained cost-effective within a WTP threshold of $50,000/QALY.

There are increasing numbers of cost-utility analyses examining breast reconstruction
options. Several have compared autologous and implant-based
reconstruction.(27,28,30,31) Overall, there is evidence to support cost-effectiveness of
autologous reconstruction. For instance, Matros et al. found DIEP flap reconstruction to
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be cost-effective relative to implant-based reconstruction with an ICER of
$11,941/Breast-QALY.(31) Another CUA found both pedicled and free autologous
reconstruction to be cost-effective within a WTP threshold of $100,000/QALY relative to
the do-nothing alternative.(27) Interestingly, that study found implant-based
reconstruction was not cost-effective as all implant-based reconstructive options
exceeded the WTP threshold. Importantly, marginal changes in utility may influence
relative cost-effectiveness.(30) Other CUAs have examined adjuncts to surgery and
surgical materials such as CT angiography and acellular dermal matrix, both of which
have been found to be cost-effective.(1,32) In terms of timing for reconstructive surgery,
single-stage, direct-to-implant reconstruction has been found to be cost effective.(26)
Thus far, no cost-utility analysis has compared saline and silicone implants. This costutility analysis provides important information to physicians, hospitals and policymakers
when purchasing implants for breast reconstruction.

Overall, silicone implants are cost-effective for implant-based breast reconstruction.
Given the improved quality of life-associated with silicone implants and only a marginal
increase in cost, this analysis supports continued use of silicone implants despite higher
initial cost.
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4. Chapter 4: General Discussion and Conclusions

Overview
This chapter reviews the results and implications of the systematic review of health
state utility values in breast reconstruction (Chapter 2) and the cost-utility analysis
comparing saline and silicone implants in breast reconstruction (Chapter 3). These
analyses add to the existing literature on utility measurement and economic analysis
in breast reconstruction by contextualizing existing health state utility values based
on methodology and by demonstrating cost-effectiveness of silicone implants in
implant-based breast reconstruction. 7

4.1. General Discussion
The purpose of this paper was to analyze the relative cost-effectiveness of saline and
silicone implants in the immediate breast reconstruction population. The rationale behind
this study is that the Canadian health care system is facing increasing fiscal limitations in
the setting of increasing demand for resources related to, among other things, the aging
population. Due to improvements in treatment and earlier detection, more women are
diagnosed with breast cancer and transitioning into the survivorship period with breast
deformities related to lumpectomy and mastectomy.

7A

portion of the work covered in Chapters 1 and 2 is included here as part of the Integrated Article
Format.
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Mastectomy in particular has increased in frequency over the years, and with it the
demand for post-mastectomy reconstructive surgery. Breast reconstruction does not
prolong life but is associated with improvement in quality of life for women in the
survivorship period.(1) Implant-based reconstruction is the most common surgical
approach.(2) Examining the quality of life changes associated with different approaches
to implant-based breast reconstruction can help find economic efficiencies as well as
justify treatments that offer significant improvements in quality of life.

This project was undertaken in two parts. First, a systematic review of the literature was
conducted to identify health state utility values (HSUVs) published in the breast
reconstruction literature. Methodological strengths of this review include the use of
multiple databases, a search strategy developed with librarian assistance and screening
undertaken by two independent reviewers. Further strengths of this analysis include a
narrative description of current methodology used to generate HSUVs in breast
reconstruction. This allows readers to better contextualize existing utilities in breast
reconstruction, especially when comparing to other illnesses. Specifically, the results
served to highlight limitations in the existing literature and discrepancies between the
most common methodology and current guidelines on HSUV generation. Finally, the
results of the quantitative analysis can serve as a reference for postoperative HSUVs in
breast reconstruction. This is one of few systematic reviews and meta-analyses on
HSUVs in breast reconstruction and is unique in its focus on values relating to postoperative complication health states.

Results of the systematic review demonstrated that the majority of reported utilities were
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generated in the context of cost-utility analyses, most commonly by surveying medical
experts (i.e., plastic surgeons) with visual analogue scales (VAS). As discussed in
Chapter 2, the VAS has some inherent bias.(3,4) Time trade-off (TTO) and standard
gamble (SG) have greater grounding in economic theory but can be more challenging to
administer.(3)

Debate exists over whether to survey experts, patients or the general public in health state
utility evaluation. It is thought that patients become accustomed to states of impaired
health and, as such, ascribed higher value to those states than healthy individuals would
ascribe. One study included in the systematic review examined HSUVs related to breast
reconstruction without nipple reconstruction (i.e., nipple deformity) by surveying the
general population and medical students.(5) These individuals ascribed a higher utility to
nipple deformity than experts ascribed to successful implant-based or autologous
reconstruction in other articles.(6–13) This study evaluated the health state using TTO,
SG and VAS with the VAS scores being slightly lower, although this difference was not
statistically significant.(5) This is consistent with estimates derived using the VAS since
these can be influenced by scaling bias, resulting in values closer to the midpoint than
with other direct elicitation techniques. Further, they found that higher medical education
influenced utility scores. Although this study is an isolated example of differences that
may be related to population surveyed and type of direct valuation technique, it is
nonetheless important to remember that these factors influence HSUVs when interpreting
or borrowing from the literature.
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The systematic review of utilities was large, returning 2249 citations. Although the
majority could be excluded based on predetermined criteria after a review of title and
abstract, there were a large number of studies that described quality of life data by patient
report. Unfortunately, the majority of these studies used ad hoc surveys and nonpreference-based health status measures, preventing this quality of life data from being
used to generate utilities in our analysis. Further, few studies reported quality of life data
with respect to complication states. Post-surgical complication states are typically of
short duration with patients returning to baseline quality of life over a period of weeks to
months. However, this limits the useful information available to translate into utility
measures. Finally, there is significant variability in the use of generic and disease-specific
health status measures. Generic tools, whether preference-based or not, allow for
comparison across different disease populations.(3) However, these can be insensitive to
changes in quality of life in surgical patients which may be temporary or based on body
image, psychosocial and sexual well-being in addition to physical well-being.(14)
Disease-specific measures tend to be better able to delineate these nuances. However, few
have passed through rigorous psychometric testing in the breast reconstruction population
resulting in poor internal and external validity.(14)

The BREAST-Q is a disease-specific, patient-reported outcome measure that was
developed using the Rasch psychometric method and provides interval level
measurement.(15) The BREAST-Q has six subscales including satisfaction with breasts,
satisfaction with outcome, psychosocial well-being, sexual well-being, chest well-being
and abdominal wall physical well-being. Items are summed for each domain and
transformed into a score ranging from 0-100. It is becoming more commonly used as a
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patient-reported quality of life metric in clinical studies and has been used for utility
generation in two cost-utility analyses.(11,16) Unfortunately, preference-rating has not
been done for the BREAST-Q. Studies that use utilities derived from BREAST-Q data
use the average score from the subscales. Utilities based on BREAST-Q scores were
included in both the quantitative analysis of utilities (Chapter 2) and the cost-utility
analysis (Chapter 3) since there is reported data on quality of life with saline and silicone
implants using this measure. Within these limitations these values constitute the best
quality of life data regarding saline and silicone implants. Because BREAST-Q-derived
utilities are based on patient opinions, the estimates may be higher than those derived
from the general population. However, because preference-weighting has not been done
for the BREAST-Q, scores do not reflect relative importance of each domain and as such
may not accurately reflect health status. This is a limitation of using BREAST-Q data to
derive utility estimates.

The results of the systematic review provide information on health state utility values
relevant to post-surgical health states in breast reconstruction. Although there are several
limitations to the validity of these HSUVs, until such time that preference weighting and
mapping functions are available for disease-specific questionnaires, they reflect the best
available quality of life data for implant-based breast reconstruction. Further, despite
these limitations, the aggregate data reported here provide a better estimate than each
individual study and can be used as more accurate estimates of HSUVs in future CUAs.

The second stage of the project involved a cost-utility analysis of saline and silicone
implants in the context of outpatient, immediate, unilateral implant-based breast
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reconstruction. Data from this analysis came from multiple sources. Utilities were
obtained from a review of the literature. Operative costing data was obtained from the
institutional case costing centre. This centre does micro-costing for Quality-Based
Procedure (QBP) groups, including reconstructive breast surgery. Micro-costing data is
used to generate average costs for QBPs which can be subdivided based on Case-Costing
Initiative (CCI) codes. The average cost for all relevant CCI codes was used as the base
operative cost. Average costs of saline and silicone implants were obtained from the
institutional purchasing centre, Healthcare Materials Management Services (HMMS).
Relevant billing codes were used to estimate surgeon and anesthesia costs.

Micro-costing involves estimation of all resource costs. In this scenario micro-costs have
been aggregated by CCI codes. Unfortunately, immediate breast reconstruction
procedures have the potential to be categorized under multiple CCI codes and, as such, a
broad scope of codes were used in an attempt to capture all relevant procedures. In doing
this, it is possible that micro-costing data from procedures not strictly immediate,
implant-based breast reconstruction were included. Further, since immediate breast
reconstruction by definition occurs during the same operation as the mastectomy, a
component of the cost estimate accounts for the surgical ablation. Since this base cost
was used as an estimate of operative costs for subsequent procedures (due to similar
operating room supplies and duration), this may constitute an over-estimation of
operative costs for subsequent procedures related to complication states. However, this
potential overestimation is applied to both saline and silicone arms of the analysis.

Implant costs were obtained from HMMS which is responsible for coordinating
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competitive bidding agreements with industry suppliers. Costs for individual implants at
St. Joseph’s Health Care (SJHC), London are protected under confidentiality agreements
so average costs of saline and silicone implants were used. Use of pricing under
competitive bidding agreements has the potential to underestimate implant-related costs;
thus, the results of this cost-utility analysis may not accurately reflect costs at institutions
without such agreements. Indeed, between London Health Sciences Centre (LHSC) and
SJHC, there were differences in the average costs of saline and silicone implants
purchased, mainly related to lower cost of saline implants (Appendix 2). Unfortunately,
because of the aforementioned confidentiality agreements, implant model type and
numbers purchased were not available, so it is unknown if the cost discrepancy was
related to the choice of implant subtype, numbers used or differences in the competitive
bidding agreements. Overall, cost-savings are expected to be similar for both saline and
silicone implants; however, small changes in implant cost may influence the degree to
which silicone implants are considered cost-effective (i.e., through changes in the ICUR).

Health state parameter estimates were obtained from the literature, specifically the
silicone Core studies and the 10-year post-market approval data for saline-filled implants
from Mentor and Allergan.(17–20) These are large, population-based, prospective studies
and provide some of the best quality data on implants and related complications. These
studies have several limitations including industry-sponsorship and the non-randomized
study design which are potential sources of bias. Unfortunately, a systematic review of
the literature on implant-related complications (Chapter 3) revealed that there are few
randomized-controlled trials and prospective, non-randomized trials directly comparing
saline and silicone implants. This is consistent with a recent Cochrane Systematic Review

93

Chapter 4
on the topic.(21) The few published randomized controlled trials were done on earlier
generations of implants and likely do not reflect the complication profile of implants in
use today.(22,23) Nonetheless, the fact that only a few studies were used to develop
parameter estimates is an inherent limitation of this analysis, which stems from the
limitations of the available literature.

Cost-utility analyses are becoming more common as stakeholders in healthcare funding
attempt to provide of high-quality services with limited resources. Several cost-utility
analyses have been published regarding breast reconstruction options. These include
comparisons of autologous and alloplastic techniques as well as adjuncts to surgery.
Within the realm of autologous reconstruction, several studies have found free tissue
transfer to be cost-effective relative to pedicled techniques. Thoma et al. found that free
TRAM was cost-effective relative to pedicled TRAM and that DIEP flap reconstruction
was cost-effective relative to TRAM flap reconstruction.(12,13) Conversely, a cost-utility
analysis done by Grover et al. found both pedicled and free autologous reconstruction to
be cost-effective with pedicled options being favoured slightly due to lower costs.(7) This
same study found implant-based reconstruction was not cost-effective relative to the donothing alternative, as it exceeded a willingness-to-pay threshold of $100,000. However,
this study was unusual in that they found only small improvements in quality-adjusted
life years for each type of approach relative to the do-nothing option. Other studies have
found autologous reconstruction to be cost-effective relative to implant-based
reconstruction. For instance, Matros et al. performed a cost-utility analysis with utilities
derived from BREAST-Q data and found that DIEP flap reconstruction was cost-effective
within a WTP threshold of $50,000, with an incremental cost-effectiveness ratio (ICER)
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of $11,941/Breast-QALY relative to implant-based reconstruction.(16) However, even
small differences in utility and cost can result in large changes in the ICUR, as
demonstrated by a Markov model developed by Preminger et al. in which cost and utility
of implant-based reconstruction and TRAM flap reconstruction were varied.(24)
Unfortunately, a significant limitation of that model was that it did not generate health
state utility values specific to each reconstructive modality and instead assumed a
baseline utility of 0.7 for both TRAM flap and implant-based reconstruction, which was
then varied in a sensitivity analysis. Nonetheless, a marginal increase in the utility of
implant-based reconstruction from 0.7 to 0.704 made implant-based reconstruction costeffective within a WTP threshold of $50,000/QALY.

Adjuncts to breast reconstruction have also been demonstrated to be cost-effective, such
as the use of CT angiography and laser-assisted indocyanine green angiography in
autologous reconstruction.(6,25) Adjuncts to implant-based reconstruction including
acellular dermal matrix may be cost-effective. One study demonstrated that acellular
dermal matrix (ADM) is cost-effective relative to staged expander-implant
reconstruction; however, another analysis suggested that autologous dermal flaps should
be used when available since these are significantly less costly than ADM with minimal
difference in quality of life.(8,9) Finally, direct-to implant reconstruction dominates
staged expander-implant reconstruction.(10)

There are no previously published cost-utility analyses comparing saline and silicone
implants in the context of breast reconstruction. Saline implants offer an initial costsavings relative to silicone implants amounting to approximately $226.60 at SJHC,
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although this is variable based on hospital and competitive bidding agreements
(Appendix 2). It can be challenging to justify devices with higher initial costs if quality of
life is not considered. When such information is taken into consideration, silicone
implants are cost-effective. Institutional variation in cost does influence the degree to
which silicone implants are cost-effective, as seen with the change in ICUR between
LHSC and SJHC data (Table 3.8). It is possible that other institutions may find variable
incremental cost-effectiveness of silicone implants due to different base price relative to
the cost of saline implants and other perioperative costs. Ultimately, silicone implants
provide improved quality of life at a marginal increase in cost relative to saline implants.
This analysis may be useful to physicians, policy-makers and hospital administrators
when justifying choice of implant in the context of breast reconstruction.
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5. Appendices
Appendix 1. Sample Calculations
Example: Weighted Average of Utility for Successful Surgery
Table A1. Values for Calculation of Utility of Successful Surgery
Article

Successful Surgery Qualifier

Utility (x)

Weight (w)1

x*w

Chatterjee et al.
2013

Free Autologous

0.85

10

8.50

Grover et al. 2013

Alloplastic Two-Stage

0.71

9

6.39

Alloplastic One-Stage

0.74

9

6.66

Pedicled Autologous

0.83

9

7.47

Free Autologous

0.85

9

7.65

Latissimus Dorsi Flap with Implant

0.74

9

6.66

0.7

5

3.50

Immediate Alloplastic Two-Stage without
ADM

0.66

10

6.60

Krishnan et al.
2013

Immediate Alloplastic One-Stage

0.74

10

7.40

Krishnan et al.
2016

Immediate Alloplastic One-Stage

0.69

15

10.35

Immediate Alloplastic Two-Stage

0.66

15

9.90

Razdan et al. 2016

Immediate Alloplastic Two-Stage

0.698

Delayed Autologous

0.692

76

52.59

Krishnan et al.
2014

Immediate Alloplastic Two-Stage with
ADM

196 136.81

Thoma et al. 2003

Autologous

0.87

33

28.71

Thoma et al. 2004

Autologous

0.87

32

27.84

Sum

447 327.03

Weighted Average Utility
1Weights

=

327.03/447

0.73

are equal to number of individuals surveyed

Worked Example – Weighted Average
!̅#$ =

∑*
)+, () #)
∑*
)+, #)

!̅#$ =

0.85∗10+0.71∗9+0.74∗9+0.83∗9+0.85∗9+0.74∗9+0.7∗5+0.66∗10+0.74∗10+0.69∗15+0.66∗15+0.698∗196+0.692∗76+0.87∗33+0.87∗32
10+9+9+9+9+9+5+10+10+15+15+196+76+33+32

!̅#$ =

:;<.=:
>><

101

Appendices
!̅#$ = 0.73
Worked Example – Weighted Standard Deviation
*

?@#$ =

E

∑
C D
F2
B )+,F ) ) GH∗!
IJ K
C
A

HGL

Where I
F=
N
?@#$ = M

∑*
)+, #)
H

and !̅ #$ =

∑*
)+, () #)
∑*
)+, #)

EO,.PQEROS
GLT∗=.<:LULEV
ER.S

L>

?@#$ = √0.005
?@#$ = 0.071
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Table A1.2 Values for Calculation of Utility of Successful Implant-Based Reconstruction
Article

Health State Qualifier

Grover et al. 2013

Alloplastic Two-Stage

0.71

9

6.39

Alloplastic One-Stage

0.74

9

6.66

0.7

5

3.50

Immediate Alloplastic Two-Stage
without ADM

0.66

10

6.60

Krishnan et al.
2013

Immediate Alloplastic One-Stage

0.74

10

7.40

Krishnan et al.
2016

Immediate Alloplastic One-Stage

0.69

15

10.35

Immediate Alloplastic Two-Stage

0.66

15

9.90

Razdan et al. 2016

Immediate Alloplastic Two-Stage

0.698

196

136.81

Krishnan et al.
2014

Utility
(x)

Immediate Alloplastic Two-Stage with
ADM

Weight
(w)1

Sum

269

Weighted Utility
1Weights

x*w

=

187.61

187.61/269

0.70

are equal to number of individuals surveyed

Table A1.3 Values for Calculation of Utility of Successful Autologous Reconstruction
Article

Health State Qualifier

Utility
(x)

Chatterjee et al.
2013

Free Autologous

0.85

10

8.50

Grover et al. 2013

Pedicled Autologous

0.83

9

7.47

Free Autologous

0.85

9

7.65

0.692

76

52.59

Razdan et al. 2016 Delayed Autologous

Weight (w)1

x*w

Thoma et al. 2003

Autologous

0.87

33

28.71

Thoma et al. 2004

Autologous

0.87

32

27.84

Sum

169

Weighted Utility
1Weights

=

are equal to number of individuals surveyed
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132.76
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Table A1.4 Values for Calculation of Utility of Total Flap Loss
Article

Health State Qualifier

Chatterjee et al.
2013

Free Autologous

0.53

10

5.30

Grover et al. 2013

Pedicled Autologous

0.58

9

5.22

Free Autologous

0.53

9

4.77

Debridement and Salvage with Tissue
Expander

0.61

33

20.13

Debredment

0.44

33

14.52

Autologous

0.61

32

19.52

Thoma et al. 2003

Thoma et al. 2004

Utility
(x)

Weight (w)1 x*w

Sum

126

Weighted Utility
1Weights

=

69.46

69.46/126

0.55

are equal to number of individuals surveyed

Table A1.5 Values for Calculation of Utility of Partial Flap Necrosis
Article

Health State Qualifier

Utility
(x)

Weight (w)1

Chatterjee et al.
2013

Free Autologous

0.77

10

7.70

Grover et al. 2013

Pedicled Autologous

0.74

9

6.66

Free Autologous

0.77

9

6.93

Partial Skin Necrosis

0.71

33

23.43

Fat Necrosis Resolves Spontaneously

0.74

33

24.42

Fat Necrosis w/ Debridement or Drain

0.69

33

22.77

Thoma et al. 2003

Thoma et al. 2004

Partial Skin Necrosis

0.71

32

22.72

Fat Necrosis Resolves Spontaneously

0.74

32

23.68

Sum

191

Weighted Utility
1Weights

x*w

=

are equal to number of individuals surveyed
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138.31/191

138.31
0.72
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Table A1.6 Values for Calculation of Utility of Mastectomy Skin Necrosis
Article

Health State Qualifier

Utility
(x)

Weight
(w)1

Chatterjee et al.
2013

Free Autologous

0.7

10

7.00

Krishnan et al.
2014

Immediate Alloplastic Two-Stage with
ADM

0.614

5

3.07

Immediate Alloplastic Two-Stage
without ADM

0.6

10

6.00

Krishnan et al.
2013

Immediate Alloplastic One-Stage

0.67

10

6.70

Thoma et al. 2004

Autologous

0.71

Sum

33
68

Weighted Utility
1Weights

x*w

=

23.43
46.20

46.20/68

0.68

are equal to number of individuals surveyed

Table A1.7 Values for Calculation of Utility of Hematoma
Article

Health State Qualifier

Utility
(x)

Weight (w)1

Chatterjee et al.
2013

Free Autologous

0.77

10

7.70

Krishnan et al.
2014

Immediate Alloplastic Two-Stage with
ADM

0.636

5

3.18

Immediate Alloplastic Two-Stage
without ADM

0.61

10

6.10

Krishnan et al.
2013

Immediate Alloplastic One-Stage

0.69

10

6.90

Krishnan et al.
2016

Immediate Alloplastic One-Stage

0.64

15

9.60

Immediate Alloplastic Two-Stage

0.6356

15

9.53

Thoma et al. 2003

Drainage Required

0.77

33

25.41

No Drainage

0.79

33

26.07

Thoma et al. 2004

Autologous

0.77

Sum
1Weights

32
163

Weighted Utility

=

are equal to number of individuals surveyed

105

x*w

119.13/163

24.64
119.13
0.73
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Table A1.8 Values for Calculation of Utility of Infection
Article

Health State Qualifier

Utility
(x)

Weight (w)1 x*w

Chatterjee et al.
2013

Free Autologous

0.75

10

7.50

Grover et al. 2013

Pedicled Autologous

0.72

9

6.48

Free Autologous

0.75

9

6.75

Immediate Alloplastic Two-Stage with
ADM

0.605

5

3.03

Immediate Alloplastic Two-Stage
without ADM

0.595

10

5.95

Krishnan et al.
2013

Immediate Alloplastic One-Stage

0.675

10

6.75

Krishnan et al.
2016

Immediate Alloplastic One-Stage

0.5802

15

8.70

Immediate Alloplastic Two-Stage

0.538

15

8.07

Thoma et al. 2003

Autologous

0.745

33

24.59

Krishnan et al.
2014

Sum

116

Weighted Utility
1Weights

=

77.81

77.81/116

0.67

are equal to number of individuals surveyed

Table A1.9 Values for Calculation of Utility of Explantation
Article

Health State Qualifier

Utility
(x)

Weight
(w)1

Krishnan et al.
2014

Immediate Alloplastic Two-Stage with
ADM

0.585

5

2.93

Immediate Alloplastic Two-Stage
without ADM

0.585

10

5.85

Immediate Alloplastic One-Stage

0.655

10

6.55

Krishnan et al.
2013
Sum

25

Weighted Utility
1Weights

=

are equal to number of individuals surveyed

106

x*w

15.33
15.33/25

0.61
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Table A1.10 Values for Calculation of Utility of Capsular Contracture Grade III/IV
Article

Health State Qualifier

Utility
(x)

Weight
(w)1

Krishnan et al.
2014

Immediate Alloplastic Two-Stage with
ADM

0.592

5

2.96

Immediate Alloplastic Two-Stage
without ADM

0.6

10

6.00

Immediate Alloplastic One-Stage

0.59

15

8.85

Immediate Alloplastic Two-Stage

0.58

15

8.70

Krishnan et al.
2016
Sum

45

Weighted Utility
1Weights

=

x*w

26.51
26.51/45

0.59

are equal to number of individuals surveyed

Table A1.11 Values for Calculation of Utility of Revision
Article

Health State Qualifier

Utility
(x)

Weight
(w)1

Krishnan et al.
2016

Immediate Alloplastic One-Stage

0.61

15

9.15

Immediate Alloplastic Two-Stage

0.62

15

9.30

Sum

30

Weighted Utility
1Weights

=

x*w

18.45
18.45/30

0.62

are equal to number of individuals surveyed

Table A1.12 Values for Calculation of Utility of Nipple Deformity
Article

Health State Qualifier

Utility
(x)

Weight (w)1

Ibrahim et al. 2015 VAS

0.84

103

86.52

TTO

0.92

103

94.76

SG

0.92

103

94.76

Sum

309

Weighted Utility
1Weights

=

are equal to number of individuals surveyed

107

276.04/309

x*w

276.04
0.89
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Table A1.13 Values for Calculation of Utility of Mastectomy Alone
Article

Health State Qualifier

Utility
(x)

Weight
(w)1

Grover et al. 2013

0.68

9

6.12

Razdan et al. 2016

0.586

71

41.61

Sum

80

Weighted Utility
1Weights

=

are equal to number of individuals surveyed

108

x*w

47.73
47.73/80

0.60
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Appendix 2. Costs Included in Case Costing Centre Procedure Estimate1
Cost Category
Direct Labour
Direct Supply
Direct Other

Included Components
Variable Direct Labour
Variable Direct Other Labour (Contracted-Out)
Variable Direct Material - General Supplies
Variable Direct Material - Patient Specific Supplies
Fixed Direct Other - Sundry
Fixed Direct Labour - Management/Operations
Fixed Direct Building, Equipment and Grounds - Equipment Expense (including
amortization), undistributed building and grounds)
Fixed Direct Labour Administration - Labour Components of the administration
departments
Fixed Direct Other - Sundry Administration - Other components of the
administration department

Fixed Indirect

Variable Indirect - Variable operating expenses from overhead functional centres
Fixed Indirect - Fixed operating expenses from overhead functional centres
1Source SJHC Case Costing Centre. 2Labour cost estimated based on cost/min of operating time.
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Appendix 3. Institutional Implant Costs
Institution
Average Implant Cost ($)1
All Implants

Saline Implants

Silicone Implants

Difference

St. Joseph's
LHSC

713.82
640.38

515
417

737.6
736.8

222.6
319.8

Average

666.34

494

737.56

243.56

1Source

HMMS April 2017 - November 2017

110

Appendices

Appendix 4. SJHC Cost Data
Health State

Silicone
Silicone Silicone
Silicone
Silicone
Saline
Successful Rupture Capsular
Unplanned Explantation Successful
Contracture Revision

Saline
Rupture

Saline
Capsular
Contracture

Saline
Saline
Unplanned Explantation
Revision

Day Surgery SJHC

6004

5781.4

5266.4

5266.4

5266.4

Procedure R119

350

350

Anesthesia R119

405.27

405.27

Preoperative Consult

81.10

47.95

47.95

47.95

47.95

81.10

47.95

47.95

47.95

47.95

First Postoperative
Follow-up Visit

41.55

41.55

41.55

41.55

41.55

41.55

41.55

41.55

41.55

41.55

Subsequent
Postoperative Followup Visit

106.2

79.65

79.65

79.65

79.65

106.2

79.65

79.65

79.65

79.65

Procedure Z135

195.95

195.95

195.95

195.95

Anesthesia Z135

315.21

315.21

315.21

315.21

Cost MRI Breast

191.15

Items
6004

5266.4

5266.4

5266.4

5781.4

0

Procedure R114

230.30

230.30

Anesthesia R114

315.21

315.21

Procedure Z142

150

150

Anesthesia Z142

165.11

165.11

MRI Breast Read

73.35

Total State Cost

6988.12

6948.81

5946.71

Total Net Cost

6988.12

13936.93 12934.83

5981.06

5750.66

6765.52

6461.71

5946.71

5981.06

5750.66

12969.18

12738.78

6765.52

13227.23

12712.23

12746.58

12516.18
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Total Net Cost 3%
Discount

N/A

12158.69 11413.03

11438.59

11267.15

N/A

11573.64

11190.43

11215.99

11044.55

Total Net Cost 1.5%
Discount

N/A

12975.68 12112.21

12141.80

11943.28

N/A

12333.36

11889.61

11919.20

11720.68

Total Net Cost 5%
Discount

N/A

11254.09 10638.88

10659.97

10518.53

N/A

10732.45

10416.28

10437.37

10295.93

112

Appendices

Appendix 5. LHSC Cost Data
Health State

Silicone
Silicone Silicone
Silicone
Silicone
Saline
Saline
Saline
Saline
Saline
Successful Rupture Capsular
Unplanned Explantation Successful Rupture Capsular
Unplanned Explantation
Contracture Revision
Contracture Revision

Items
Day Surgery LHSC

4804

4804

4067.2

4067.2

4067.2

4484.2

4484.2

4067.2

4067.2

4067.2

Procedure R119

350

350

Anesthesia R119

405.27

405.27

Preoperative Consult

81.10

47.95

47.95

47.95

47.95

81.10

47.95

47.95

47.95

47.95

First Postoperative
Follow-up Visit

41.55

41.55

41.55

41.55

41.55

41.55

41.55

41.55

41.55

41.55

Subsequent Postoperative 106.2
Follow-up Visit

79.65

79.65

79.65

79.65

106.2

79.65

79.65

79.65

79.65

Procedure Z135

195.95

195.95

195.95

195.95

Anesthesia Z135

315.21

315.21

315.21

315.21

Cost MRI Breast

191.15

0

Procedure R114

230.30

230.30

Anesthesia R114

315.21

315.21

Procedure Z142

150

150

Anesthesia Z142

165.11

165.11

MRI Breast Read

73.35

Total State Cost

5788.12

5675.46

4747.51

Total Net Cost

5788.12

11463.58 10535.63

4781.86

4551.46

5468.32

5164.51

10569.98

10339.58

5468.32

10632.83 10215.83
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4781.86

4551.46

10250.18

10019.78
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Total Net Cost 3%
Discount

10011.20 9320.71

9346.27

9174.83

9311.20

9000.91

9026.47

8855.03

Total Net Cost 1.5%
Discount

10678.48 9878.89

9908.49

9709.96

9918.41

9559.09

9588.69

9390.16

Total Net Cost 5%
Discount

9272.36

8723.77

8582.32

8638.88

8382.88

8403.97

8262.52

8702.68
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Appendix 6. Decision Tree for LHSC Data
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